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ABBREVIATIONS 
14-3-3 
proteins 
family of proteins defined by their chromatographic migration
pattern 
3C chromosome conformation capture 
AD Addison’s disease 
AIRE autoimmune regulator 
AIRE-Tet HEK293 cell line with doxycycline-inducible AIRE expression 
AP-1 activating protein 1 
APS1 autoimmune polyendocrinopathy syndrome 1 
ATM ataxia telangiectasia mutated protein 
ATR ataxia telangiectasia and Rad3 related protein 
BAI3 brain-specific angiogenesis inhibitor 3 
BAT2 large proline-rich protein BAT2 
BCR B-cell receptor 
BIR baculovirus IAP repeat protein domain 
BPTF bromodomain PHD finger transcription factor 
BRCT tandem breast cancer susceptibility protein domain 
BRD4 bromodomain-containing protein 4 
CARD caspase recruitment domain 
CBP CREB-binding protein (CBP) 
CD4/8 cluster of differentiation 4 or 8 
CDH11 cadherin 11 
CDK7/9 cyclin-dependent kinase 7 or 9 
CEACAM carcinoembryonic antigen-related cell adhesion molecule 
ChIP chromatin immunoprecipitation 
ChIP-seq ChIP coupled with high-throughput sequencing 
CHST13 carbohydrate sulphotransferase 13 
CLDN1 claudin 1 
CMC chronic mucocutaneous candidiasis 
CNS1 conserved non-coding sequence 1 
CpG 5'-cytosine-phosphate-guanine-3'  
CREB cAMP response element-binding protein 
cRNA complementary RNA 
CT chromosome territory 
CTCF CCCTC-binding factor 
Ctcfl CCCTC-binding factor like protein 
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CTD RNAP II C-terminal domain 
cTEC cortical thymic epithelial cell 
Ctrl uninduced/untreated AIRE-Tet cells 
CXCR7 C-X-C chemokine receptor type 7 
DAPI 4',6-diamidino-2-phenylindole 
DC dendritic cell 
DEAF1 deformed epidermal autoregulatory factor 1 
DMEM Dulbeccos’s Modified Eagle Medium 
DNA-PK DNA-dependent protein kinase 
Dox doxycycline-treated AIRE-Tet cells 
Dox+Etop doxycycline-induced and etoposide-treated AIRE-Tet cells 
DPF3 double PHD fingers 3 protein 
ECL enhanced chemicluminescence 
EDTA ethylenediaminetetraacetic acid 
ENCODE Encyclopedia of DNA Elements 
eTAC extra-thymic AIRE-expressing cell 
Etop etoposide-treated AIRE-Tet cells 
Ets E-twenty-six family transcription factor 
FAIRE formaldehyde-assisted isolation of regulatory elements 
FAS Fas cell surface death receptor 
FBS fetal bovine serum 
FOG1 friend of GATA1 protein 
FOS proto-oncogene c-Fos 
FOSL1 FOS like antigen 1 
FOXO1 forkhead box O1 transcription factor 
FOXP3 forkhead box 3 transcription factor 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GATA1 GATA (nucleotide sequence) binding protein 1 
γH2AX histone H2AX phosphorylated at serine 139 
GMEB glucocorticoid modulatory element binding protein 
GST glutathione S-transferase 
H3K27me3 histone H3 trimethylated at lysine 27 
H3K36me3 histone H3 trimethylated at lysine 36 
H3K4me0/3 histone H3 unmethylated or trimethylated at lysine 4 
H3K9me3 histone H3 trimethylated at lysine 9 
H3S10ph histone H3 phosphorylated at serine 10 
H4K16ac histone H4 acetylated at lysine 16 
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H4K20me3 histone H4 trimethylated at lysine 20 
HBG2 haemoglobin subunit gamma 2 
HEK-AIRE HEK293 cell line with constitutive AIRE expression 
HEK-AIRE. 
K243/253Q 
HEK293 cell line with constitutive AIRE.K243/253Q expression 
HEK-YFP HEK293 cell line with constitutive yellow fluorescent protein
expression 
HEK293 human embryonic kidney cell line 293 
HEK293T human embryonic kidney cell line 293 expressing the simian
vacuolating virus 40 large T antigen 
HMGB1 high mobility group protein B1 
Hox homeobox-containing transcription factor 
HP hypoparathyroidism 
HP1 heterochromatin protein 1 
HPRT1 hypoxanthine phosphoribosyltransferase 1 
HRP horseradish peroxidase 
IAP baculovirus inhibitor of apoptosis 
ICD interchromatin domain 
IF immunofluorescence 
IFI16 interferon gamma inducible protein 16 
IgG normal goat serum IgG 
IP immunoprecipitation 
Irf4/8 interferon regulatory factor 4 or 8 
ISGF3 interferon-stimulated gene factor 3 
IVL involucrin 
JAK-STAT Janus kinase and signal transducer of activator of transcription
signalling pathway 
Jmjd6 JmjC Domain-Containing Protein 6 
K[DN]WK lysine-[aspartic acid/asparagine]-tryptophan-lysine sequence motif 
KAT8 lysine acetyltransferase 8 
KMT1A lysine methyltransferase 1A 
KRT73 keratin 73 
Ku70/Ku80 70 or 80 kDa subunit of Ku antigen 
LPL lipoprotein lipase 
LXXLL Leu-Xaa-Xaa-Leu-Leu amino acid sequence motif 
LY6G6D lymphocyte antigen 6 family member G6D 
mChIP modified chromatin immunoprecipitation 
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MHC major histocompatibility complex 
MHCIIhi high expression of MHC class 2 molecules 
mTEC medullary thymic epithelial cell 
NCBI National Center for Biotechnology Information 
NF-Y nuclear factor Y 
NF-κB nuclear factor kappa B family of transcription factors 
NGS normal goat serum 
NLS nuclear localisation signal 
NucP41/P75 nuclear protein 41 kDa/75 kDa 
NUDR nuclear DEAF1-related protein 
P-TEFb positive transcription elongation factor b 
p300 adenovirus early region 1A-associated 300 kDa protein 
PAPLN papilin, proteoglycan like sulphated glycoprotein 
PARP1 poly [ADP-ribose] polymerase 1 
PBS phosphate-buffered saline 
PCAF p300/CBP-associated factor 
PCR polymerase chain reaction 
PDYN prodynorphin 
PHD1/2 plant homeodomain 1 or 2 
PML promyelocytic leukaemia protein 
PRC1/2 polycomb repressive complex 1 or 2 
PRR proline-rich region 
PSMD4 proteasome 26S subunit, non-ATPase 4 
PTM post-translational modification 
PWWP proline-tryptophan-tryptophan-proline sequence containing protein 
domain 
qPCR quantitative polymerase chain reaction 
Rad3 protein kinase rad3 
RING really interesting new gene type zinc finger domain 
RIPA radio immunoprecipitation assay 
RNAi RNA interference 
RNAP II RNA polymerase II 
Rtt109 regulator of Ty1 transposition protein 109 
S100A10 S100 calcium binding protein A10 
S100A8 S100 calcium binding protein A8 
SAND SP100, AIRE1, NucP41/P75 and DEAF1 protein domain 
SDS-PAG sodium dodecyl sulphate polyacrylamide gel 
12 
SEM standard error of the mean 
Sirt1 sirtuin 1 deacetylase 
SIRT2 sirtuin 2 deacetylase 
SKP2 S-phase kinase-associated protein 2 
Sp1 specificity protein 1 
SP100 speckled protein 100 kDa 
STAT1/2 transducer and activator of transcription 1 or 2 
TAD topologically associated domain 
TAF250 TATA (nucleotide sequence) binding protein-associated factor 
250 kDa protein 
Tbx21 T-box protein 21 
Tcf7 T-cell factor 7 
TCR T-cell receptor 
TFIIE/F/H transcription factor II E, F or H 
TOP1 DNA topoisomerase 1 
TOP2A/B DNA topoisomerase 2-alpha or 2-beta 
TRA tissue-restricted antigen 
Treg regulatory T-cell 
TSA Trichostatin A 
Ty1 yeast transposon 1 
Ube3a ubiquitin-protein ligase E3A 
WB western blot 
YFP yellow fluorescent protein 
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1. INTRODUCTION 
The immune system has major role in maintaining the homeostasis of the 
organism by reacting to and eliminating invading pathogens as efficiently as 
possible, while preventing harmful effects to the body’s own cells and tissues. 
However, the immune effector cells can become dangerous to self and contribute 
to autoimmunity if the molecular mechanisms of immune tolerance fail for 
some reason. Autoimmune disorders are mainly complex diseases that correlate 
with genetic and environmental factors, but the causal order of cellular and 
molecular events that lead to the pathological condition are often poorly 
understood.  
The autoimmune polyendocrinopathy syndrome 1 (APS1) is a rare exception 
where the cause can be traced back to the deficiency of a single gene – the 
autoimmune regulator (AIRE) gene. APS1 manifests in adverse immune reactions 
against multiple organs in conjunction with loss of immunity to fungal infections. 
The expression of the AIRE protein is almost exclusively limited to the 
medullary thymic epithelial cells (mTECs) where AIRE acts as transcriptional 
regulator of thousands of genes that are considered to be tissue-restricted 
antigens (TRAs). The expressed TRAs are fragmented and the self-peptides are 
loaded onto the major histocompatibility complex (MHC) proteins, which react 
with the intact T-cell receptor (TCR) of the developing thymocytes. Thymocytes 
that have high affinity toward self-peptides undergo apoptosis, which helps to 
establish and maintain immunological tolerance.  
Although the fundamental principles of many of the events outlined above 
have gained ever deeper insight, the details of the molecular mechanisms 
governing AIRE-dependent gene expression remain elusive and under intense 
scientific debate. AIRE is now known to partner with tens of nuclear proteins 
that affect transcription, chromatin structure, nuclear shuttling and RNA 
splicing. Furthermore, the structural features of the chromatin, including histone 
modifications, at AIRE target gene loci and the post-translational modifications 
of AIRE itself have been associated with AIRE activity. Yet, how all these 
interactions, structural and biochemical alterations jointly shape the AIRE-
mediated gene activation remains to be explored. The modern high-throughput 
and single cell technologies have confirmed many earlier observations about the 
transcriptional program present in AIRE-expressing cells and, hopefully, will 
create new opportunities to solve the puzzle of promiscuous gene expression in 
the thymus. 
The current thesis presents results that establish the role of post-translational 
acetylation of the AIRE protein in AIRE-dependent transcription, describes the 
pathological mutation in the second zinc finger domain of AIRE and characterises 
the AIRE-driven changes in chromatin structure at AIRE target genes and 
beyond.  
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2. REVIEW OF LITERATURE 
2.1. The mechanisms of immune tolerance 
The immune system comprises of two major compartments that are distinguished 
by their timing and specificity towards infectious agents. First, the cells and 
molecules of the innate immune system react rapidly to any invading pathogens 
by responding to molecular patterns and signals that are common to large 
groups of microorganisms. Second, a persistent immune reaction will eventually 
activate the components of the adaptive immune system, which detect and 
eliminate pathogens with great specificity. 
The specificity is achieved by a reaction between the B- or T-cell receptor on 
the cell membrane of a B or T lymphocyte and an antigenic molecule, which the 
B-cells encounter in the extracellular space and the T-cells recognise as bound 
to a MHC complex on other cell types, including specialised antigen presenting 
cells (Kyewski and Klein, 2006; Pelanda and Torres, 2012). The two compart-
ments are tightly connected through signalling molecules and cell-cell inter-
actions, which greatly increase the efficiency of clearing an infection. However, 
harmless airborne and food compounds or molecules that derive from the 
organism itself have antigenic properties, but in that case, it is important to 
exclude them from being targeted by any immune defence response. The 
organism manages it by applying a multitude of molecular and cellular mecha-
nisms that dampen the effector signals or eliminate the autoreactive lymphocytes 
altogether resulting in the so-called immune tolerance. 
The processes that deprive lymphocytes of activating signals occur mainly in 
the secondary lymphoid organs and are commonly referred to as peripheral 
immune tolerance mechanisms. The majority of studies on peripheral tolerance 
conclude that the lymphocytes survive, but become anergic to their cognate 
antigen, although increased apoptosis of self-reactive mature T- and B-cells has 
also been described (Mueller, 2010; Pelanda and Torres, 2012). 
The primary lymphoid organs, the thymus and the bone marrow, are 
responsible for the central immune tolerance, which mainly encompasses the 
removal or reprogramming of autoreactive lymphocytes during their development 
before they enter the blood circulation and the lymphatic system. According to 
estimates, 50–70% of differentiating B lymphocytes in the bone marrow are 
autoreactive, of which up to 50% undergo B-cell receptor (BCR) editing and the 
other half are restrained by immunological anergy or ignorance (Grandien et al., 
1994; Wardemann et al., 2003). 
In the thymus, the developing T lymphocytes have to pass through a more 
dramatic maturation process including a positive and a negative selection stage 
where approximately 90% of all thymocytes die by apoptosis (Klein et al., 
2014). The positive selection takes place at the thymic cortex where immature 
cluster of differentiation 4 and 8 (CD4 and CD8, respectively) double-positive 
thymocytes need to have a fully functional TCR that can interact with a self-
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peptide-MHC complex on the surface of the cortical thymic epithelial cells 
(cTECs), dendritic cells (DCs) or fibroblasts and thereby avoid dying by neglect 
(Klein et al., 2009). The surviving thymocytes migrate into the thymic medulla 
where they undergo negative selection where the cells that carry a TCR with 
high affinity towards self-peptide-MHC complexes on mTECs will receive a 
death signal, which leads to apoptosis (Starr et al., 2003). Finally, differentiated 
single-positive CD4 or CD8 thymocytes that have a functional TCR with low 
affinity for self-peptide-MHC complexes are released to the periphery as mature 
naive T-cells (Starr et al., 2003). Several studies suggest that in parallel with 
negative selection the thymic medulla promotes also the emergence of regulatory 
T-cells (Tregs) from the same pool of autoreactive thymocytes (Apostolou et 
al., 2002; Fontenot et al., 2005; Itoh et al., 1999; Jordan et al., 2001). 
In any case, failure in tolerance may result in an autoimmune disorder where 
one or multiple tissues are targeted and gradually destroyed by the autoreactive 
immune cells (Antonia et al., 1995; Asano et al., 1996; Kishimoto and Sprent, 
2001; Lesage et al., 2002). Common autoimmune disorders have a polygenic 
background and the severity of the disease is heavily dependent on a complex 
interplay between the risk alleles and environmental factors. Yet, few rare 
autoimmune syndromes follow an autosomal recessive mode of inheritance and 
are strongly linked to mutations in single key genes, such as in the autoimmune 
regulator (AIRE), forkhead box P3 (FOXP3) transcription factor and the Fas cell 
surface death receptor (FAS) genes (Aaltonen et al., 1997; Chatila et al., 2000; 
Fisher et al., 1995; Nagamine et al., 1997). Of these, FOXP3 and FAS are 
necessary for the development and availability of T-cell populations, and AIRE 
is pivotal in the process of negative selection (Cheng and Anderson, 2012). 
 
 
2.2. The autoimmune regulator and the autoimmune 
polyendocrinopathy syndrome 1 
The human AIRE gene covers a 12.8 kb region on chromosome 21q22.3. Its 14 
exons encode a protein of 545 amino acid residues and a molecular weight of 
57.7 kDa (Aaltonen et al., 1997; Nagamine et al., 1997) (Figure 1). 
Mutations in the AIRE gene can cause APS1 which mainly manifests in three 
pathological conditions: chronic mucocutaneous candidiasis (CMC), hypo-
parathyroidism (HP) and Addison’s disease (AD) (Neufeld et al., 1981). 
Usually, the patients suffer from additional clinical complications with large 
variations in the time of onset and severity (Husebye et al., 2009). 
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In most cases, APS1 has a classical autosomal recessive mode of inheritance, 
where only biallelic mutations result in the disease (Ahonen, 1985). To date, 
more than 100 mutations in the AIRE coding sequence have been uncovered 
and the number increases due to ever increasing availability of modern 
sequencing and genotyping technologies (www.hgmd.cf.ac.uk). Some patients 
display an autosomal dominant pattern of inheritance, for example, the carriers 
of the SP100, AIRE1, NucP41/P75 and DEAF1 (SAND) domain mutation 
G228W or six missense mutations found in the plant homeodomain 1 (PHD1) 
zinc finger domain (Cetani et al., 2001; Oftedal et al., 2015). Based on exome 
array data, dominant-negative AIRE mutations are rather frequent within the 
general population suggesting that more organ-specific autoimmune diseases 
than previously thought of could be due to the expression of a dysfunctional 
AIRE protein (Oftedal et al., 2015). 
 
 
2.2.1. The regulation of AIRE expression 
The AIRE locus is silenced in most tissues and its expression can mainly be 
detected in mTECs, and to a far lesser extent in thymic DCs, thymic B-cells, 
extra-thymic AIRE-expressing cells (eTACs), testis, ovary and fetal tissues 
(Gardner et al., 2008; Halonen et al., 2001; Heino et al., 1999, 2000; Nishikawa 
et al., 2010; Schaller et al., 2008; Yamano et al., 2015). The AIRE promoter 
region harbours several conserved binding sequences for multiple transcription 
factors, including specificity protein 1 (Sp1), nuclear factor Y (NF-Y), 
activating protein 1 (AP-1), and E-twenty-six (Ets) family proteins (Murumägi 
 
Figure 1. The human AIRE gene and protein. The vertical red bar on the chromosome 
21 ideogram shows the location of the AIRE gene (human reference genome version 
38). The AIRE gene structure is depicted together with the location of 5'-cytosine-
phosphate-guanine-3' (CpG) islands and the PhyloP conservation score. The arrow 
shows the upstream conserved non-coding sequence 1 (CNS1). The AIRE protein 
contains the following domains and sequence motifs: caspase recruitment domain 
(CARD); the nuclear localisation signal (NLS); the SP100, AIRE1, NucP41/P75 and 
DEAF1 (SAND) domain; plant homeodomain 1 and 2 (PHD1 and PHD2); proline-rich 
region (PRR); the Leu-Xaa-Xaa-Leu-Leu amino acid sequence motifs (LXXLL). 
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et al., 2003, 2006). In addition, the upstream sequence of AIRE contains a CpG 
island both in humans and mice and its methylation status has been linked to the 
control of AIRE expression in several cell lines and in thymic epithelial cells 
(Herzig et al., 2016; Kont et al., 2011; Murumägi et al., 2003) (Figure 1). 
Two recent studies published the role of a highly conserved enhancer 
element ~3 kb upstream of the AIRE gene locus that is critically important in 
mediating the activation of the expression of AIRE by nuclear factor kappa B 
(NF-κB) signalling (Haljasorg et al., 2015; LaFlam et al., 2015) (Figure 1). 
Furthermore, mice lacking the enhancer sequence displayed a phenotype similar 
to AIRE knock-out mice (Haljasorg et al., 2015; LaFlam et al., 2015). 
Another layer of complexity in the regulation of AIRE expression was 
discovered by Yanagihara et al. (2015) who found that the splicing of the AIRE 
transcript is impaired in mice deficient for the arginine demethylase and lysine 
hydroxylase called JmjC domain-containing protein 6 (Jmjd6), which is known 
to modify several splicing regulatory proteins. Although AIRE transcript levels 
were normal, the retained intron 2 severely hampered the translation of a 
functional AIRE protein (Yanagihara et al., 2015). 
A large-scale study to uncover the complex network of transcriptional 
regulators that are necessary to facilitate AIRE expression in the thymic cell 
compartments identified four transcription factors – namely interferon 
regulatory factor 4 (Irf4), interferon regulatory factor 8 (Irf8), T-box protein 21 
(Tbx21) and T-cell factor 7 (Tcf7) – that contribute to the efficient expression 
of AIRE (Herzig et al., 2016). In addition, this report described the role of the 
insulator protein CCCTC-binding factor (CTCF) in maintaining a silenced 
AIRE locus and showed that its eviction by the CCCTC-binding factor like 
(Ctcfl) protein allowed the recruitment of the aforementioned transcription 
factors (Herzig et al., 2016). 
 
 
2.2.2. The structure and cellular localisation of the AIRE protein 
The structural domains of AIRE highlight its role in the cell nucleus, particu-
larly in chromatin-related processes (Figure 1). The N-terminal 105 amino acids 
belong to the caspase recruitment domain (CARD), which mediates the formation 
of homo-oligomers (Ferguson et al., 2008). The CARD domain is followed by a 
bipartite nuclear localisation signal (NLS) and putative NLS further upstream 
(Saltis et al., 2008). The SAND domain is known to bind DNA via the lysine-
(aspartic acid/asparagine)-tryptophan-lysine (K[DN]WK) sequence motif and 
depends on the underlying CpG methylation status (Bottomley et al., 2001; 
Isaac et al., 2006; Jensik et al., 2014). Two reports have demonstrated that AIRE 
could bind DNA in sequence-specific manner and the protein-DNA interaction 
was mapped to the SAND and PHD domains (Kumar et al., 2001; Purohit et al., 
2005). However, the canonical motif is missing in AIRE SAND domain and a 
more recent study showed that the AIRE CARD domain rather than the SAND 
domain is required to interact with nucleosome-free DNA, which in this case 
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lacked any sequence-specificity (Maslovskaja et al., 2015). The AIRE protein 
contains two PHD-type zinc fingers that serve as modules for protein-protein 
interactions and are essential for the activation of AIRE target genes (Koh et al., 
2008; Org et al., 2008; Yang et al., 2013). Notably, the electrostatic surface of 
the AIRE PHD1 has a negative overall charge that facilitates its binding to 
histone H3 that is unmethylated at lysine 4 (H3K4me0), which is a characteristic 
feature of silenced genomic regions (Koh et al., 2008; Org et al., 2008). The 
PHD2 domain structure resembles that of PHD1, but it has a positively charged 
surface, which implies that it mediates a different set of protein-protein 
interactions (Gaetani et al., 2012; Yang et al., 2013). The AIRE protein also has 
a uncharacterised proline-rich region between the PHD zinc fingers and four 
LXXLL motifs, which are part of many regulatory proteins in the nucleus and 
are required for protein-protein interactions, for example, with nuclear receptors 
(Plevin et al., 2005). 
The AIRE protein localises into the cell nucleus and forms dot-like struc-
tures called AIRE nuclear bodies, which resemble, but do not overlap with pro-
myelocytic leukaemia protein (PML)-containing nuclear bodies (Akiyoshi et al., 
2004; Heino et al., 1999). Mutations in the AIRE CARD domain disrupt the 
punctate pattern in the nucleus, although other protein domains have also been 
reported to influence the subcellular localisation of AIRE (Björses et al., 1999; 
Ferguson et al., 2008; Halonen et al., 2004; Ramsey et al., 2002; Rinderle et al., 
1999). AIRE has been shown to interact and colocalise with the acetyl-
transferase cAMP response element-binding protein (CREB)-binding protein 
(CBP), which is also known to interact with PML (Doucas et al., 1999; Pitkänen 
et al., 2000, 2005). CBP and its paralog adenovirus early region 1A-associated 
300 kDa protein (p300) are able to post-translationally acetylate AIRE, thereby 
modulating the transcriptional activity of AIRE (Chuprin et al., 2015; Incani et 
al., 2014). Intriguingly, AIRE also co-localises with the deacetylase protein 
sirtuin-1 (Sirt1), which was reported to directly counteract the effort of 
CBP/p300 to modify AIRE (Chuprin et al., 2015). Similarly to PML nuclear 
bodies, the core of the AIRE nuclear bodies is devoid of chromatin and RNA 
polymerase II (RNAP II) suggesting that these structures do not participate in 
transcription (Pitkänen et al., 2005). Nevertheless, the AIRE nuclear bodies are 
bound to the nuclear matrix and might affect transcriptional processes indirectly 
through shaping the chromatin landscape (Abramson et al., 2010; Akiyoshi et 
al., 2004; Tao et al., 2006). 
 
 
2.2.3. Transcriptional regulation by AIRE 
The AIRE protein is a transcriptional regulator that can potentially activate 
more than 3000 different genes in a phenomenon called promiscuous gene 
expression, which allows the AIRE-expressing cells to represent almost the 
entire protein coding portion of every other tissue in the body (Anderson et al., 
2002; Derbinski et al., 2001; Sansom et al., 2014). The molecular mechanisms 
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behind this extraordinary transcriptional program have been difficult to dissect 
due to technical challenges that are related to the scarcity of primary cells 
expressing AIRE. For example, the number of AIRE-positive mTECs in a 
mouse thymus is less than 50,000 (Anderson and Su, 2016). However, modern 
single-cell based molecular genomics approaches have started to resolve this 
issue and give more detailed insights into the gene regulatory mechanisms 
governing AIRE-dependent gene expression. Single-cell RNA-seq studies have 
shown that mTECs express the TRA genes with ordered stochasticity meaning 
that individual mTECs express a somewhat random set of TRA genes, which 
however tend to cluster on the chromosomes or co-express interchromosomally, 
but often lack any other obvious common features, such as belonging to the 
same signalling or metabolic pathway (Brennecke et al., 2015; Meredith et al., 
2015). On a population level, this permits mTECs to present a vast array of self-
peptides to the developing thymocytes and give the crucial signals to elicit 
negative selection (Brennecke et al., 2015; Meredith et al., 2015). 
Two proteomic screens and many small-scale pull-down experiments with 
AIRE have identified over 40 interaction partners that could be broadly divided 
into 4 functional groups – proteins related to transcription, chromatin structure/ 
remodelling, mRNA splicing and nuclear transport (Abramson et al., 2010; 
Gaetani et al., 2012). As mentioned above, AIRE partners with the unmethy-
lated histone H3, although this reaction itself has low affinity suggesting that it 
is a short-term dynamic interaction (Koh et al., 2008; Org et al., 2008). AIRE-
responsive genomic regions tend to be also enriched for repressive histone 
marks, such as histone H3 trimethylated at lysine 27 (H3K27me3), and low 
levels of acetylated histones or histone H3 trimethylated at lysine 4 (H3K4me3) 
(Org et al., 2009; Sansom et al., 2014). However, direct binding of AIRE to 
those modified histones has not been demonstrated. Furthermore, chromatin 
immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) 
analyses have shown that AIRE can be recruited to almost every gene promoter 
irrespective of its transcriptional status, but only at loci in a silenced chromatin 
environment does AIRE display its transcriptional potential (Giraud et al., 
2012). 
Increasing evidence supports the hypothesis that AIRE facilitates the release 
of the poised RNAP II at silenced sites by binding to the positive transcription 
elongation factor b (P-TEFb) and allowing it to phosphorylate the pause factors 
and RNAP II, which then enters the elongation phase (Giraud et al., 2014; Oven 
et al., 2007). A more recent study reported that the interaction between AIRE 
and P-TEFb is, in fact, mediated by the bromodomain-containing protein 4 
(BRD4), which is known to recruit P-TEFb through its C-terminal domain 
(Yoshida et al., 2015). Interestingly, BRD4 bound AIRE via its bromodomains 
that interacted with lysine residues in the CARD domain that had been 
acetylated by CBP (Yoshida et al., 2015). 
A notably large group of AIRE interaction partners participate in the DNA 
damage response, such as the DNA topoisomerase 2-alpha (TOP2A), DNA-
dependent protein kinase (DNA-PK) and its non-catalytic 70 and 80 kDa 
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subunits of Ku antigen (Ku70/Ku80), and poly [ADP-ribose] polymerase 1 
(PARP1) (Abramson et al., 2010; Gaetani et al., 2012; Liiv et al., 2008; Yang et 
al., 2013). TOP2A generates transient DNA breaks to resolve torsional tension 
in supercoiled DNA, which is caused by an elongating DNA or RNA 
polymerase (Nitiss, 2009). Double-stranded DNA breaks activate the DNA-
PK/Ku70/Ku80 complex, which then phosphorylates many nuclear proteins that 
will initiate the DNA repair process (Callén et al., 2009). DNA-PK can also 
phosphorylate AIRE at several serine and threonine residues, although the role 
of phosphorylation in AIRE-dependent gene activation is still under debate 
(Liiv et al., 2008; Zumer et al., 2012). Nevertheless, mutation analysis of two 
amino acid positions in the CARD domain – threonine 69 and serine 157 – that 
are potentially modified by DNA-PK suggested that phosphorylation could be a 
prerequisite for CBP-dependent acetylation, which is necessary for the 
interaction with the aforementioned BRD4 (Yoshida et al., 2015). 
Additional investigations on AIRE acetylation have revealed a complex 
interplay between different modified lysine residues and the functionality of 
AIRE. Acetylation of the lysine residues within the NLS sequence decreases 
AIRE target gene activation by hindering the localisation of AIRE into the 
nucleus (Incani et al., 2014). On the other hand, the deacetylase Sirt1 promotes 
the transcription of AIRE-dependent genes by specifically removing acetyl 
groups from lysines between the NLS and SAND domain (Chuprin et al., 2015). 
Although the mechanistic links and the chain of molecular events regarding 
AIRE-dependent gene activation have become clearer, the current knowledge 
cannot explain why this occurs only at certain and not all genes that are targeted 
by AIRE.  
 
 
2.3. Linking chromatin structure and transcription 
The basic chromatin structure is highly conserved among the eukaryotes from 
yeast to mammals, although the complexity increases towards the more recent 
groups of organisms. The low-level unit of the chromatin is the nucleosome 
core, which consists of a 147 bp DNA sequence wrapped around a histone 
octamer. The histone octamer is comprised of four pairs of histones H2A, H2B, 
H3 and H4. Nucleosome cores are connected by a variable-length linker DNA 
sequence which on average adds up to 200 bp of nucleosomal DNA (Davey et 
al., 2002; Luger et al., 1997). Nucleosomes are 11 nm in diameter and are thought 
to be further packaged into 30 nm fibres with the help of linker histone H1, 
which is structurally distinct from the other four histones (Vignali and Workman, 
1998). Gene expression is thought to be tightly linked to the level of chromatin 
condensation. In general, chromatin is classified into compact and transcriptio-
nally silent heterochromatin and into more accessible and transcriptionally 
active euchromatin. Modern genomics approaches have started to unravel the 
finer organisation of the genome allowing to distinguish not only actively 
transcribed regions from heterochromatin, but also detect the spatio-temporal 
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regulation of chromatin looping, topologically associated domains, chromosome 
territories, the nuclear lamina and transcription factories (Bolzer et al., 2005; 
Dixon et al., 2012; Kadauke and Blobel, 2009; Verschure et al., 2002). 
Chromatin loops form between genomic regulatory elements, such as 
enhancers and promoter, which can be separated by kilo- or megabases of DNA 
of the same chromosome. The widespread adoption of chromosome conformation 
capture (3C)-based methods in functional genomics has significantly accelerated 
the discovery of gene regulatory events. High-resolution maps of chromatin 
loops reveal the role of promoter-enhancer interactions in transcriptional control 
(Jin et al., 2013; Lieberman-Aiden et al., 2009; Rao et al., 2014; Sanyal et al., 
2012). Evidence from recent reports suggests that enhancer competition 
determines the rate of transcription of different genes that rely on the availability 
of the same enhancer (Rao et al., 2014; Sanyal et al., 2012). Often, the position 
of the enhancer relative to the genes does not matter, and interestingly, as little 
as 7% of enhancers interact with the closest gene (Rao et al., 2014; Sanyal et al., 
2012). Chromatin looping may also depend on the differentiation stage of the 
cells. For example, transcription factors required for the activation of the α-
globin gene are bound to the enhancer located 40 kb away of the locus already 
at an early proerythroblast stage, although only at the late erythroblast stage 
does the enhancer interact with the promoter and permit the transcription of α-
globin (Vernimmen et al., 2007). 
Topologically associated domains (TADs) are large structures consisting of 
several chromatin loops and usually defined by the relatively frequent intra-
TAD interactions as compared to inter-TAD interactions (Dixon et al., 2012; 
Nora et al., 2012). It has been proposed that TADs could divide the chromatin 
into regions that have similar activity. Many genes that are co-regulated in 
development and clustered on chromosomes belong to the same TAD (Nora et 
al., 2012). Also, genes responding differentially to external stimuli have been 
shown to group together in different TADs (Le Dily et al., 2014). 
Chromatin looping as well as the formation of TADs require architectural 
proteins, such as the CTCF and cohesin complex, which bind chromatin 
insulator sequences, thereby blocking promoter-enhancer interactions or 
heterochromatin spreading (Gaszner and Felsenfeld, 2006). DNA-bound CTCF 
can dimerise with another distally positioned CTCF, which effectively creates 
chromatin loops (Guo et al., 2012). Furthermore, ChIP-seq studies have 
revealed that the CTCF-dependent loops display a cell type-specific pattern and 
the disruption of the CTCF or cohesin binding sites can significantly alter the 
expression of nearby genes (Nora et al., 2012; Zuin et al., 2014; Tark-Dame et 
al., 2014). The depletion of architectural proteins enriched at TAD borders has 
been found to increase the frequency of inter-TAD interactions (Li et al., 2015). 
The non-random nature of the genome organisation extends to whole 
chromosomes not only at the critical stages of cell division, but also at other cell 
cycle phases. The phenomenon of chromosomes taking up specific regions in 
the nucleus with respect to one another and to the nuclear lamina has been termed 
chromosome territories (CTs) (Cremer and Cremer, 2010). Furthermore, the 
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position of genes within the CTs tends to be predetermined. Namely, actively 
transcribed loci are more likely to be found looping out at the periphery of CTs 
and silenced genomic regions are more frequently located in the interior of CTs 
(Federico et al., 2008; Kurz et al., 1996; Mahy et al., 2002; Scheuermann et al., 
2004). However, additional investigations are necessary to clarify whether gene 
repositioning is the cause or consequence of altered expression. For example, in 
human embryonic stem cells, the actively transcribed homeobox (Hox) gene 
loops out of its CT together with genes whose expression remains constant 
(Morey et al., 2009). Other findings support the hypothesis that loops outside of 
the CTs represent regions of poised chromatin ready for activation. According 
to knock-down experiments, the extrusion of the human β-globin locus from its 
CT prior to activation depends on the activities of the transcription factor 
GATA nucleotide sequence binding protein 1 (GATA1) and its co-regulator 
friend of GATA1 (FOG1) protein (Ragoczy et al., 2003). However, RNA 
interference (RNAi)-mediated depletion of FOG1 after the β-globin gene had 
looped out of the CT did not affect β-globin expression (Lee et al., 2011). 
The radial positioning of CTs and genes therein adds another layer of 
complexity and gene regulatory features that should be taken into account when 
studying the relationship between transcription and genome organisation. 
Notably, it has been observed that chromosomal regions close to the nuclear 
lamina become transcriptionally silenced, whereas genes located more centrally 
within the nucleus are actively expressed (Croft et al., 1999; Scheuermann et 
al., 2004; Tanabe et al., 2002). Furthermore, the latter active transcription sites 
tend to be highly enriched for proteins belonging to the transcriptional 
machinery, including phosphorylated RNAP II, transcription and splicing factors, 
which has been collectively referred to as transcription factories (Branco and 
Pombo, 2006; Bridger et al., 2005; Cisse et al., 2013; Verschure et al., 2002). 
Transcription factories tend to occupy the nuclear space between CTs called the 
interchromatin domain (ICD), which is believed to foster the optimal conditions 
for efficient transcription by facilitating the colocalisation of genes and 
regulatory sequences from different CTs, while minimising the likelihood of 
ectopic contacts (Iborra et al., 1996). Further analyses have found that 
constitutively active transcription factories are complemented with poised 
transcription factories that become highly activated in a stimulus-response 
manner (Ferrai et al., 2010). 
Although it is unknown how the compartmentalisation is controlled and 
what mechanisms rearrange the nuclear organisation in response to external 
signals, it is clear that the compartmentalisation of the nucleus provides an 
efficient and quick mode to regulate gene activation and silencing.  
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2.3.1. The role of topoisomerases in shaping chromatin structure 
and transcription 
A moving polymerase generates positive DNA supercoils ahead of the 
polymerase complex and negative supercoils behind it (Liu and Wang, 1987). 
The overwound DNA in front of the polymerase prevents DNA strand sepa-
ration, which can inhibit the nucleic acid synthesis (Liu and Wang, 1987). The 
supercoils are detected and bound by DNA topoisomerases that can cleave one 
or both DNA strands, unwind the DNA thereby relieving torsional stress in the 
molecule and re-ligate the strands back together (Champoux, 2001). There are 
two main types of DNA topoisomerases that are classified based on their 
catalytic activity. Type I topoisomerases (TOP1 in humans) cut a single strand 
and rotate it around the intact strand releasing both positive and negative 
supercoils after which the DNA break is sealed (Pommier et al., 1998). Type II 
topoisomerases (TOP2A and TOP2B in humans) create a double-strand DNA 
break, pass the intact part of the double helix through the break to remove 
mainly positive supercoils and close the break (Gale and Osheroff, 1992). 
In addition to binding to distorted chromatin structures and altering their 
topology, the topoisomerase activity, similarly to other DNA damage-causing 
conditions, changes the histone modification pattern. More specifically, the 
chromatin at sites of double-stranded DNA breaks, which can be induced by 
topoisomerases or other DNA-damaging processes, becomes enriched for the 
histone H2A variant H2AX, which is phosphorylated by either ataxia 
telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR) or 
DNAP-PK at serine 139 (γH2AX) (Durocher and Jackson, 2001). The region 
marked by γH2AX can spread around the DNA break for several hundred 
kilobases (Savic et al., 2009). 
In addition to being vitally important in DNA replication and recombination, 
both types of topoisomerases have also been implicated in RNA transcription 
(Puc et al., 2017). Transcription has been shown to be attenuated after RNAi-
mediated depletion of any of the topoisomerases suggesting that topoisomerases 
facilitate RNAP II processivity (Brill et al., 1987; Gartenberg and Wang, 1992; 
Goto and Wang, 1985; Kim and Wang, 1989; Schultz et al., 1992). Indeed, 
studies with yeast and human cells have shown that TOP1 is enriched at highly 
expressed genes where it physically binds to the phosphorylated C-terminal 
domain of the RNAP II catalytic subunit (Baranello et al., 2016; Phatnani et al., 
2004; Takahashi et al., 2011). In addition, TOP1 is recruited to transcriptionally 
active sites through interactions with chromatin remodelling factors (Husain et 
al., 2016). Importantly, the TOP1-RNAP II interaction stimulates the TOP1 
DNA relaxation activity that facilitates promoter escape and elongation past 
natural pause sites (Baranello et al., 2016). 
Intriguingly, TOP1 and TOP2 are critical for the transcription of extremely 
long genes in human neurons. Investigations have determined that the 
expression of long genes linked to autism spectrum disorder can be attenuated 
by TOP1 inhibitors or the knock-down of TOP1 and TOP2B genes (King et al., 
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2013). Furthermore, the blocking of TOP1 and TOP2 activity by small-molecule 
inhibitors reduces the expression of an anti-sense transcript that silences the 
paternal ubiquitin-protein ligase E3A (Ube3a) allele in Angelman syndrome 
(Huang et al., 2011). 
 
 
2.4. Post-translational modifications  
in transcriptional regulation 
Transcription relies on a coordinated series of protein-protein and protein-DNA 
interactions. All steps in this process are accompanied by the catalysis of 
chemical moieties onto chromatin proteins, such as histones, or components of 
the general transcription machinery, including the RNAP II, and transcription 
factors bound to distal regulatory elements (Chen et al., 2011; Hendriks and 
Vertegaal, 2016; Phatnani and Greenleaf, 2006; Spange et al., 2009; Suganuma 
and Workman, 2011). 
The best studied post-translational modifications (PTMs) have so far been 
histone acetylation, methylation and phosphorylation, which have been shown 
to correlate well with the transcriptional state of a genomic locus (Suganuma 
and Workman, 2011). For example, the molecular events leading to the 
activation of the proto-oncogen c-Fos (FOS) like antigen 1 (FOSL1) gene in 
human embryonic kidney cell line 293 (HEK293), involve the phosphorylation 
of serine 10 on histone H3 (H3S10ph) at the FOSL1 enhancer allowing the 
binding of 14-3-3 protein, which is required by the lysine acetyltransferase 8 
(KAT8) to acetylate histone H4 lysine 16 (H4K16ac) (Zippo et al., 2009). 
H3S10ph and H4K16ac enable the binding of BRD4 through its bromodomain, 
which brings the transcription elongation factor P-TEFb to the promoter (Zippo 
et al., 2009). In the transcription initiating phase, the RNAP II is already 
phosphorylated by the cyclin-dependent kinase 7 (CDK7) subunit of the 
transcription factor II H (TFIIH) at the 5th position of the heptameric repeat on 
its C-terminal domain (CTD) (Sansó and Fisher, 2013). Only after the cyclin-
dependent kinase 9 (CDK9) subunit of the P-TEFb has phosphorylated the 2nd 
position of the heptad repeats on the CTD does the RNAP II enter the 
transcription elongation phase (Sansó and Fisher, 2013). Actively transcribed 
sites acquire additional histone modifications, such as the H3K4me3 in the 
promoter flanking the transcription start site and histone H3 lysine 36 tri-
methylation (H3K36me3) along the gene body (Barski et al., 2007). Although 
studies in yeast have shown that neither H3K4me3 nor H3K36me3 are required 
for the transcription, the presence of those modifications does increase the 
efficiency of the RNA polymerase (Mason and Struhl, 2005; Zhang et al., 
2005). 
Similarly, gene silencing is accompanied by specific histone modifications 
that serve as docking sites for regulators that repress transcription. The tri-
methylation of histone H3 lysine 9, 20 and 27 (H3K9me3, H4K20me3 and 
H3K27me3, respectively) are all known to correlate with silenced chromatin 
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regions (Suganuma and Workman, 2011). Typically, these regions also lack 
histone acetylation, H3K4me3 and H3K36me3, although all these modifications 
have been found in various combinations in reciprocal chromatin states (Barski 
et al., 2007).  
In general, the constitutive heterochromatin found at pericentromeric regions, 
is enriched for H3K9me3, which is bound by the heterochromatin protein 
1 (HP1) (Lachner et al., 2001). This interaction is proposed to facilitate chro-
matin folding and the packaging into higher-order structures (Fan et al., 2004; 
Maison et al., 2002; Peters et al., 2001; Thiru et al., 2004). Furthermore, the 
interaction between HP1 and the lysine methyltransferase 1A (KMT1A) is 
thought to facilitate the spreading of H3K9me3 (Lachner et al., 2001).  
Facultative heterochromatin, which is found at developmental and imprinted 
gene loci, is characterised by the presence of H3K27me3 (Trojer and Reinberg, 
2007). This histone mark is established by the polycomb repressive complex 
2 (PRC2) and bound by polycomb repressive complex 1 (PRC1) that can 
actively block ATP-dependent chromatin remodelling and RNAP II activity (Cao 
et al., 2002; King et al., 2002; Kuzmichev et al., 2002; Levine et al., 2002). The 
PRC1 also contains E3 ubiquitin ligase activity specifically towards histone H2A 
lysine 119 whose monoubiquitylation has been shown to correlate with the 
binding of linker histone H1, which is considered to contribute to the main-
tenance of a repressive chromatin state (de Napoles et al., 2004; Zhu et al., 
2007; Wang et al., 2004).  
The proteins that catalyse, bind to and remove the PTMs are often referred to 
as PTM writers, readers and erasers, respectively, although in many cases these 
functions are intermingled in the same protein complex (Patel and Wang, 2013). 
Recent structural analyses have uncovered large families of protein domains 
that have specialised in interacting with certain PTMs. For example, the 
chromodomain, Tudor and proline-tryptophan-tryptophan-proline (PWWP) and 
PHD zinc finger domains bind to methylated lysine or arginine residues by a 
surface groove pocket recognition mode (Chen et al., 2011; Ruthenburg et al., 
2007). The role of these structures in regulating transcription is evidently 
dependent on the surrounding chromatin context and the interaction partners, 
because both gene activating and silencing complexes harbour methyl-lysine or 
-arginine binding functions (Patel and Wang, 2013). Bromodomains, which are 
part of many acetyltransferases, methyltransferases, chromatin remodelling and 
co-activator complexes, have high affinity towards acetylated lysines (Dhalluin 
et al., 1999). Phosphorylated amino acids are bound by the 14-3-3, tandem breast 
cancer susceptibility (BRCT) and baculovirus inhibitor of apoptosis (IAP) repeat 
(BIR) domain-containing proteins (Kelly et al., 2010; Mackintosh, 2004; Singh 
et al., 2012). An additional layer of complexity in the signalling cascades 
involving PTMs comes from the observations that the PTM-binding domains 
are found in tandem or in combination, for example the tandem PHD fingers in 
the double PHD fingers 3 (DPF3) protein or the PHD-bromodomain cassette in 
the bromodomain PHD finger transcription factor (BPTF) (Lange et al., 2008; 
Li et al., 2006). Notably, some of these structures are specialised to interact with 
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unmodified amino acid residues, including the AIRE PHD1 and the PHD finger 
protein 21A (PHF21A) PHD domain (Koh et al., 2008; Lan et al., 2007; Org et 
al., 2008). 
In summary, numerous studies highlight the involvement of PTMs in the 
regulation of protein function and suggest a complex crosstalk between PTMs 
and their readers to maintain the high specificity of gene expression regulation. 
 
 
2.4.1. Transcription regulation by the acetylation  
of non-histone proteins 
The lysine acetylation has been implicated to modulate the DNA and protein 
binding, subcellular localisation, protein stability and catalytic activity of a 
variety of non-histone proteins in both nuclear and cytoplasmic compartments 
(Glozak et al., 2005). 
The earliest reported acetylated non-histone protein was the tumour 
suppressor p53, which is modified by the acetyltransferase and transcription co-
activator protein p300, which leads to an increase in sequence-specific DNA 
binding by p53 (Gu and Roeder, 1997). Follow-up studies have elaborated on 
the role of p53 acetylation in transcriptional control of its target genes and 
revealed an intricate interplay with other post-translational modifications. 
Namely, acetylation competes with ubiquitylation for the same lysine residues 
in the p53 protein sequence. Lysine polyubiquitylation marks proteins for 
proteasomal degradation and, therefore, the mutually exclusive relationship 
between the two modifications determines the stability of p53 (Ito et al., 2002). 
Furthermore, the acetylation of lysine 373 by p300 and the subsequent 
transcription of the cyclin-dependent kinase inhibitor p21 during a DNA 
damage response are stimulated by the methylation of lysine 372 (Ivanov et al., 
2007). 
Acetylation can also decrease the activity of a transcription factor. Studies 
have shown that the acetylation of certain lysine residues of the forkhead box 
O1 (FOXO1) transcription factor by CBP decreases FOXO1 affinity to DNA 
and stimulates its subsequent phosphorylation (Matsuzaki et al., 2005). The 
phosphorylated FOXO1 protein is bound by 14-3-3 proteins and exported out of 
the nucleus into the cytoplasm where it is polyubiquitylated and degraded by 
the proteasome (Brunet et al., 1999). Additional studies have shown that the 
activities of the deacetylase sirtuin 2 (SIRT2) can maintain FOXO1-mediated 
transcription, which strengthen the notion that acetylation can control FOXO1 
activity (Jing et al., 2007). 
In addition to stimulating protein phosphorylation of the components of the 
Janus kinase and signal transducer and activator of transcription (JAK-STAT) 
pathway (Rawlings et al., 2004) , interferon-signalling has also been shown to 
promote CBP-mediated acetylation of the signal transducer and activator of 
transcription 2 (STAT2) protein in the cytoplasm, which enables it to dimerise 
with signal transducer and activator of transcription 1 (STAT1) and form the 
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interferon-stimulated gene factor 3 (ISGF3) complex (Tang et al., 2007). The 
acetylated ISGF3 can translocate to the nucleus and activate the transcription of 
interferon-responsive genes (Tang et al., 2007). Furthermore, the NLS sequences 
often contain lysine residues that are modified by acetyltransferases. The  
S-phase kinase-associated protein 2 (SKP2) is acetylated by p300 at its NLS, 
which promotes the nuclear export of SKP2 (Inuzuka et al., 2012). SKP2 is an 
E3 ubiquitin ligase that ubiquitylates E-cadherin, which results in the 
degradation of E-cadherin and thereby contributes to the cell migration and 
survival in the context of tumorigenesis (Inuzuka et al., 2012). Acetylation of 
the cytoplasmic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
by p300/CBP-associated factor (PCAF) allows it to translocate into the nucleus 
where it participates in transcriptional regulation and DNA repair (Ventura et 
al., 2010). 
Several transcription coactivators, including CBP/p300, KAT8 and the yeast 
regulator of Ty1 transposition 109 (Rtt109) are able to autoacetylate themselves 
(Stavropoulos et al., 2008; Thompson et al., 2004; Yuan et al., 2012). The 
autoacetylation within the activation loop motif of CBP/p300 is triggered by 
protein dimerisation, which in turn activates the enzyme (Karanam et al., 2006). 
This sequence of events is further confirmed by findings showing that the 
deacetylase SIRT2 is able to attenuate p300 activity (Black et al., 2008). The 
transcription co-activators TATA nucleotide sequence binding protein-asso-
ciated factor 250 kDa (TAF250), PCAF, and p300 can also acetylate the general 
transcription factors IIE amd IIF (TFIIE and TFIIF, respecitvely), although the 
functional consequences of these modifications are unclear (Imhof et al., 1997). 
Taken together, post-translational acetylation of transcription regulators 
plays a multifaceted role in shaping the transcriptional output of the cell. The 
altered biochemical properties of the acetylated proteins can render them 
inactive or strengthen their transcriptional potential. A growing amount of 
evidence highlights the regulatory interplay with other modifications and 
between acetylation events of different lysine residues on the same protein. 
 
 
2.5. Summary of the literature 
The characterisation of the AIRE protein has greatly helped to gain a deeper 
insight into the mechanisms of central immune tolerance. Although the key 
events have been described in detail (Abramson and Goldfarb, 2016; Anderson 
and Su, 2016), many of the underlying molecular processes that lead to the 
activation of thousands of TRA genes are still elusive and require more attention.  
Proteomic screenings have determined dozens of nuclear proteins that 
directly bind AIRE (Abramson et al., 2010 and Study III). Many AIRE inter-
action partners possess enzymatic activities which can activate or inhibit 
transcriptional regulators or modify chromatin proteins. However, the exact role 
of most of the partner proteins and their enzymatic activities in shaping the 
function of AIRE are poorly understood. 
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Currently, more than 100 mutations have been found along the AIRE gene 
coding sequence that can be causally linked to APS1 (www.hgmd.cf.ac.uk). A 
large fraction of the detected mutations fall into the functional domains CARD, 
PHD1 and PHD2. Yet, the molecular basis of the disease-causing mutations and 
their relationship to the severity of the disease are often unclear and need to be 
addressed more thoroughly. 
Chromatin at actively transcribed regions is considered to be loosely 
packaged by histones making it easily accessible for transcription-related 
proteins, including the RNA polymerase II (Campos and Reinberg, 2009). 
However, AIRE tends to regulate the expression of genes that are located at 
repressed chromatin regions (Anderson et al., 2002; Derbinski et al., 2001; 
Sansom et al., 2014). Despite considerable effort from many research groups, 
the process of how AIRE determines its target gene repertoire has remained 
enigmatic and is of high scientific interest to date. 
The current thesis touches some of the aspects of AIRE-dependent transcrip-
tion that involve the analysis of post-translational modifications, the effects of 
missense mutations and changes in the chromatin structure.  
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3. AIMS OF THE STUDY 
The aims of the present study were: 
1. To functionally characterise the impact of post-translational acetylation of 
the AIRE protein by the transcription coactivator and acetyltransferase p300. 
2. To investigate the effect of the previously identified APS1-associated 
mutation C446G in the AIRE PHD2 domain on protein-protein interactions 
and AIRE-dependent transcriptional regulation. 
3. To determine the alterations in chromatin accessibility and CTCF-mediated 
chromatin conformation that are linked to the expression of AIRE.  
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4. MATERIALS AND METHODS 
4.1. Cloning of reporter and expression plasmids 
Plasmids that were used in the transfections are listed in Table 1. 
  
Table 1. The list of expression plasmids that were used in the study. 
Plasmid name Reference 
pcAIRE (Heino et al., 1999) 
pcAIRE.K243Q Described in Study I 
pcAIRE.K245Q Described in Study I 
pcAIRE.K253Q Described in Study I 
pcAIRE.K243/245Q Described in Study I 
pcAIRE.K243/253Q Described in Study I 
pcAIRE.K243R Described in Study I 
pcAIRE.K245R Described in Study I 
pcAIRE.K253R Described in Study I 
pcAIRE.K243/245R Described in Study I 
pcAIRE.K243/253R Described in Study I 
pcDNA3-AIRE Described in Study II 
pCDNA3-AIRED297A Described in Study II 
pCDNA3-AIREV301M Described in Study II 
pCDNA3-AIREC446G Described in Study II 
GST-AIRE-C446G Described in Study II 
pBL-INV (Liiv et al., 2008)  
pCMVβ-p300.wt-Myc Gift from T-P. Yao, Department of Pharmacology and 
Cancer Biology, Duke University 
pCMVβ-p300.DY-Myc Gift from T-P. Yao, Department of Pharmacology and 
Cancer Biology, Duke University 
pRc/RSV-mCBP-HA-RK Gift from R. Goodman, Oregon Health and Science 
Institute 
pcDNA3-FLAG/mouse 
PCAF(WT) 
Gift from T. Nakajima, Institute of Medical Science, St. 
Marianna University School of Medicine 
pcDNA3-FLAG/mouse 
PCAF(ΔHAT) 
Gift from T. Nakajima, Institute of Medical Science, St. 
Marianna University School of Medicine 
pd2EYFP-N1 Clontech, Mountain View, CA, USA 
pcDNA3.1B(-)Myc/His Invitrogen, Carlsbad, CA, USA 
pGEX-1ZT-SH3 Gift from Dr. K. Saksela, University of Tampere 
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The acetylation site mutations were created by PCR-based site-directed muta-
genesis by using the pcAIRE expression plasmid as template (Heino et al., 
1999). The PCR-amplified fragments were cloned into the BamHI/HindIII sites of 
pcAIRE, which resulted in the following expression plasmids: pcAIRE.K243Q, 
pcAIRE.K245Q, pcAIRE.K253Q, pcAIRE.K243/245Q, pcAIRE.K243/253Q, 
pcAIRE.K243R, pcAIRE.K245R, pcAIRE.K253R, pcAIRE.K243/245R and 
pcAIRE.K243/253R. The primers for the mutagenesis and cloning are listed in 
Table 2. 
 
Table 2. The list of primers for the site-directed mutagenesis and cloning used in the 
study. 
Mutation Primer name Sequence Template 
 F1 (508-529  
AIRE cDNA) 
GCAGAGCAGCAGCGCCT
TCCAC 
pcAIRE 
 R1 (pcDNA3.1 
BGH) 
GGCAACTAGAAGGCACA
GTCGAGGC 
pcAIRE 
AIRE.K243Q K243Q F CCGGCAGTGGGCAGAAC
AAGGC 
pcAIRE 
 K243Q R GGCCTTGTTCTGCCCACT
GCCG 
pcAIRE 
AIRE.K245Q K245Q F GTGGGAAGAACCAGGCC
CGCAG 
pcAIRE 
 K245Q R GCTGCGGGCCTGGTTCT
TCCCA 
pcAIRE 
AIRE.K253Q K253Q F CAGTGGCCCGCAGCCTC
TGGTT 
pcAIRE 
 K253Q R ACCAGAGGCTGCGGGCC
ACTGC 
pcAIRE 
AIRE.K243/245Q K243Q/K245Q F TGGGCAGAACCAGGCCC
GCAGC 
pcAIRE.K243Q 
 K243Q/K245Q R CTGCGGGCCTGGTTCTG
CCCAC 
pcAIRE.K243Q 
AIRE.K243/253Q K253Q F CAGTGGCCCGCAGCCTC
TGGTT 
pcAIRE.K243Q 
 K253Q R ACCAGAGGCTGCGGGCC
ACTGC 
pcAIRE.K243Q 
AIRE.K243R K243R F CGGCAGTGGGAGGAACA
AGGCC 
pcAIRE 
 K243R R GGGCCTTGTTCCTCCCAC
TGCC 
pcAIRE 
AIRE.K245R K245R F TGGGAAGAACAGGGCCC
GCAGC 
pcAIRE 
 K245R R TGCTGCGGGCCCTGTTCT
TCCC 
pcAIRE 
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Mutation Primer name Sequence Template 
AIRE.K253R K253R F AGTGGCCCGAGGCCTCT
GGTTC 
pcAIRE 
 K253R R AACCAGAGGCCTCGGGC
CACTG 
pcAIRE 
AIRE.K243/245R K243R/K245R F TGGGAGGAACAGGGCCC
GCAGC 
pcAIRE.K243R 
 K243R/K245R R TGCTGCGGGCCCTGTTC
CTCCC 
pcAIRE.K243R 
AIRE.K243/253R K253R F AGTGGCCCGAGGCCTCT
GGTTC 
pcAIRE.K243R 
 K253R R AACCAGAGGCCTCGGGC
CACTG 
pcAIRE.K243R 
 
 
4.2. Cell culture and transfection 
All cell culture experiments were performed with transiently transfected or 
established stably expressing human embryonic kidney epithelial cell line 
HEK293. The latter include HEK293 cells with constitutive AIRE, AIRE.K243/ 
253Q or yellow fluorescent protein expression (HEK-AIRE, HEK-AIRE.K243/ 
253Q and HEK-YFP, respectively) in Study I and HEK293 cells with 
doxycycline-inducible AIRE expression (AIRE-Tet) in Study III. Except for 
AIRE-Tet, the cell lines were grown in Dulbeccos’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-
antimycotic solution (all components were purchased from PAA Laboratories). 
The AIRE-Tet cell line was grown in selective DMEM supplemented with 10% 
tetracycline-negative FBS, 1% antibiotic-antimycotic solution (both were 
purchased from PAA Laboratories) and 0.15 mg/ml geneticin G418 (Sigma-
Aldrich). The cells were kept at 37 °C with 5% CO2. The cells were transfected 
at 60–70% confluency with ExGen 500 in vitro Transfection Reagent according 
to manufacturer’s protocol (Fermentas). Depending on the following assay, the 
transfected cells were harvested at 24 or 48 h time point. Each experiment was 
performed in duplicate and repeated at least three times. Cells transfected with 
an empty vector were used as negative control samples. 
 
 
4.3. Antibodies 
Antibodies that were used in the western blot (WB), immunoprecipitation (IP), 
chromatin immunoprecipitation (ChIP) and immunofluorescence (IF) experi-
ments are listed in Table 3. 
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Table 3. The list of primary and secondary antibodies that were used in the study. 
Antibody Description Methods Product reference 
Anti-AIRE 6.1 Primary mouse 
monoclonal to human 
AIRE protein 
WB, IP Purified in-house 
Anti-AIRE Primary goat polyclonal 
to human AIRE protein 
WB, IF EB05507, Everest 
Biotech Ltd 
Anti-acetyl lysine Primary rabbit polyclonal 
to acetylated lysines 
WB, IP 06-933, Upstate/EMD 
Millipore 
Anti-GAPDH Primary mouse 
monoclonal [6C5] to 
human GAPDH protein 
WB ab8245, Abcam 
Anti-p300 (C-20) Primary rabbit polyclonal 
to human p300 protein 
WB sc-585, Santa Cruz 
Biotechnology 
Anti-tubulin Primary mouse 
monoclonal to human 
tubulin 
WB T9026, Sigma-Aldrich 
Anti-histone H3 Primary rabbit polyclonal 
to histone H3 
WB ab1791, Abcam 
Anti-gamma H2A.X Primary rabbit polyclonal 
to histone γH2AX 
ChIP ab2893, Abcam 
Anti-HMGB1 Primary rabbit polyclonal 
to HMGB1 
ChIP ab18256, Abcam 
Anti-H1 Primary goat polyclonal 
to histone H1 
ChIP sc-34464, Santa Cruz 
Biotechnology 
Anti-mouse-IgG-HRP Horseradish peroxidase-
conjugated secondary 
antibody to mouse IgG 
protein 
WB NA9310, GE 
Healthcare 
Anti-rabbit-IgG-HRP Horseradish peroxidase-
conjugated secondary 
antibody to rabbit IgG 
protein 
WB NA9340, GE 
Healthcare 
Alexa Fluor 488 anti-
mouse IgG (H+L) 
Secondary goat antibody 
to mouse IgG conjugated 
with Alexa 488 
IF A11029, Invitrogen 
 
Alexa Fluor 4594 anti-
rabbit IgG (H+L) 
Secondary goat antibody 
to rabbit IgG conjugated 
with Alexa 594 
IF A11037, Invitrogen 
 
 
  
34 
4.4. Immunofluorescence and microscopy 
Cells were fixed with 3% formaldehyde in phosphate-buffered saline (PBS) for 
20 min at 22 °C followed by 2 × 5 min washes with PBS. The fixed cells were 
permeabilised with 0.5% Triton X-100/1% normal goat serum (NGS) for 
10 min at 22 °C followed by 3 × 10 min washes with PBS containing 1% NGS. 
The cells were incubated with primary and secondary antibodies for 1 h with 
2 × 10 min washes with PBS containing 1% NGS in between. Finally, the cells 
were washed 4 × 10 min including the staining of the nuclei with 4',6-
diamidino-2-phenylindole (DAPI, 1:5000 dilution) during the third wash. The 
cells were covered with Fluorescent Mounting Medium (DakoCytomation) and 
the staining results were captured with the LSM5 DUO laser confocal 
microscope (Zeiss) at the Core Facility of Visualisation and Screening at the 
University of Tartu, Estonia. 
 
 
 
  
 
4.5. Immunoprecipitation 
The cells were scraped off of the 15 cm tissue culture plates and washed twice 
with ice-cold PBS and the pellet was lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS) supplemented with protease inhibitors (5 µg/ml leu-
peptin, 5 µg/ml aprotinin, 200 µg/ml 4-(2-aminoethyl)benzenesulfonyl fluo-
ride), phosphatase inhibitors (50 mM NaF, 0.2 mM Na3VO4), histone deacetylase 
inhibitor (10 mM Na-butyrate) and 50 µM ZnCl2 to stabilise AIRE zinc fingers. 
Lysates were kept on ice for 10 min and clarified by centrifugation at 16000 × g 
for 10 min at 4 °C. The supernatants were incubated with the AIRE 6.1 anti-
body (Table 3) or NGS for 2 h at 4 °C. The immune complexes were pre-
cipitated with Protein G SepharoseTM 4 Fast Flow (GE Healthcare) for another 
2 h at 4 °C. To prepare samples for mass-spectrometry, AIRE was precipitated 
with cyanogen bromide-activated SepharoseTM 4B (GE Healthcare) conjugated 
with anti-AIRE 6.1 antibody. The Sepharose beads were washed 3 × 1 ml low 
salt wash buffer (20 mM Tris-HCl pH 8.1, 150 mM NaCl, 2mM ethylene-
diaminetetraacetic acid (EDTA), 0.1% SDS, 1% Triton X-100), 2 × 1 ml high 
salt wash buffer (20 mM Tris-HCl pH 8.1, 500 mM NaCl, 2 mM EDTA, 0.1% 
SDS, 1% Triton X-100) and 1 × 1 ml TE (10 mM Tris-HCl pH 7.4, 1 mM 
EDTA). The protein was eluted from the Sepharose beads with 30–40 µl 2× 
Laemmli buffer (Laemmli, 1970) and heated for 5 min at 95 °C. The immuno-
precipitation samples were analysed by western blotting (see section 4.6) and 
mass-spectrometry, which was performed as a service at the Core Laboratory of 
Proteomics in the Institute of Technology, University of Tartu, Estonia. 
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4.6. Western blot 
Immunoprecipitation samples or cell lysates were loaded onto an 8% sodium 
dodecyl sulphate polyacrylamide gel (SDS-PAG) and run for 15 min at 80 V 
followed by 30 min at 150 V on a Mini-PROTEAN Electrophoresis System (Bio-
Rad Laboratories). The separated proteins were transferred to ImmobilonTM-P 
polyvinylidene difluoride membranes (Millipore) for 20 min at 15 V on a 
Trans-Blot semidry electrophoretic transfer cell (Bio-Rad Laboratories). The 
membranes were blocked with 5% (w/v) skimmed milk or 5% (w/v) bovine 
serum albumin in TBST buffer (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% 
Tween 20) overnight at 4 °C. The membranes were incubated with primary and 
secondary antibodies for 1 h with 2 × 10 min washes with 5% skimmed milk/ 
TBST buffer in between. The final 3 × 10 min washes with 5% skimmed milk/ 
TBST buffer were followed by 1 min incubation with ECL Advance Western 
Blotting Reagent (GE Healthcare). The protein signals were captured on X-ray 
films (Fuji) or by the ImageQuantTM-RT ECL image analysis system (GE 
Healthcare). 
 
 
 
4.8. Luciferase activation assays 
The HEK293 cells were grown and transfected as described in section 4.2. 
Luciferase reporter assays were performed at 48 h time point after transient 
transfection. The cells were lysed with 1× lysis buffer (Promega) and incubated 
with the luciferase substrate according to the Luciferase Assay System kit 
protocol (Promega). Luminescence was counted with Wallac 1420 Victor 
Multilabel/Plate Reader (Perkin Elmer).  
 
 
4.9. RNA purification and quantitative real-time PCR 
The total RNA from transfected cells was purified with TRIzol (Invitrogen) 
according to manufacturer’s instructions. For complementary DNA synthesis, 3–
5 µg of total RNA was processed with the SuperScript III First-Strand Synthesis 
 
4.7. Protein stability assay 
The cells were treated with protein translation inhibitor cycloheximide (40 µg/ml) 
24 h after transfection and lysed with 2× Laemmli buffer (Laemmli, 1970) at 0, 
2, 4, and 6 h time points. The lysates were processed for western blotting as 
described in section 4.6. The protein signals were captured and quantified by 
the ImageQuantTM-RT ECL image analysis system (GE Healthcare). The AIRE 
protein signals were normalised to the signal of the housekeeping protein 
GAPDH. 
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System (Invitrogen) according to manufacturer’s instructions. Quantitative PCR 
(qPCR) was performed with the ABI Prism 7900 HT Fast Real-Time PCR 
System (Applied Biosystems) using the qPCR SYBR Green Core Kit (Euro-
gentec). All reactions were performed in triplicates and experiments were 
repeated at least twice. The expression values were normalised to the hypoxan-
thine-guanine phosphoribosyltransferase 1 (HPRT1) housekeeping gene. The 
fold difference relative to a control sample was assessed by the comparative Ct 
method (Applied Biosystems). The expression analysis primers are listed in 
Table 4. At least one primer from each pair was designed to cover an exon-exon 
boundary to increase the specificity of the PCR reactions. 
 
Table 4. List of expression analysis primers used in the study. 
Gene Primer name Sequence 
S100A8 Hu_S100A8_F CTCAGTATATCAGGAAAAAGGGTGCAGAC 
 Hu_S100A8_R CACGCCCATCTTTATCACCAGAATGAG 
IVL Hu_IVL_F GCCTTACTGTGAGTCTGGTTGACA 
 Hu_IVL_R GGAGGAACAGTCTTGAGGAGCT 
HBG2 Hu_HBG2_F CATAAAGCACCTGGATGATCTC 
 Hu_HBG2_R CAGGAGCTTGAAGTTCTCAG 
PDYN Hu_PDYN1_F TGCCTTTGTTCTATTTTTGCAGGT 
 Hu_PDYN1_R CAGCAATTCCTGCGGCTTG 
KRT73 Hu_KRT73_F GAGTGCAGGATGTCCGGAGAATA 
 Hu_KRT73_R TTGCTGAATCCAAAGCCAGCC 
CEACAM5 Hu_CEA5_F CCTGGATGTCCTCTATGGGC 
 Hu_CEA5_R TACTGCGGGGATGGGTTAGA 
PSMD4 Hu_PSMD4_F GAAGGTGAAAGAGACTCA 
 Hu_PSMD4_R GTCATACTGCTTAGGTCA 
HPRT Hu_HPRT_F GACTTTGCTTTCCTTGGTCAGG 
 Hu_HPRT_R AGTCTGGCTTATATCCAACACTTCG 
BAI3 BAI3 F GCAGCGATGCCCTGCACCTT 
 BAI3 R GGTGCCTGTGGCATTCAGGGG 
CDH11 CDH11 F CGTGCTTGTGGGCAGGCTTCA 
 CDH11 R TGTCCACCGCCTGAGCCATCA 
IFI16 hIFI16_exp_F CTGTGAGGAAGGAGATAAACTG 
 hIFI16_exp_R TCTTGATGACCTTGATGTGAC 
CHST13 CHST13 F CTCCCTGCGCCCGGCATTTG 
 CHST13 R CGTGAGTGGCGGCTACAGGC 
PAPLN PAPLN F TGACTGCAGCGCGGAGTGTG 
 PAPLN R CCCTGCCTTCCAGCGCTTGG 
CXCR7 CXCR7 F CTGCAGCCAGCAGAGCTCACA 
 CXCR7 R GAGGCGGGCAATCAAATGACCTCC 
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Gene Primer name Sequence 
CLDN1 h_CLDN1_expr_F AATTCTATGACCCTATGACCC 
 h_CLDN1_expr_R GACAGGAACAGCAAAGTAGG 
LY6G6D hLY6G6D_exp_F TGGAACAGATCAAGCTACCT 
 hLY6G6D_exp_R CTCTGTCTCCACTTGATTGC 
LPL hLPL_exp_F TGCTTGAGTTGTAGAAAGAACC 
 hLPL_exp_R TTGGTAATGGAAGACTTTGTAGG 
BAT2 h_BAT2_expr_for CCAGAGCAAATCTTACCCAG 
 h_BAT2_expr-rev TACTGTAACCTGCTGGAGAG 
S100A10 S100A10_for TCCCTGGATTTTTGGAAAATCAAAAAGACC 
 S100A10_rev CCCGCAATTAGGGAAAAGAAGCTCTGGAA 
 
 
4.10. Gene expression array 
Total RNA from HEK-AIRE, HEK-AIRE.K243/253Q and HEK-YFP cells was 
isolated with TRIzol (Invitrogen) according to manufacturer’s instructions. 
Samples were treated with Turbo DNase (Ambion) to remove traces of genomic 
DNA and purified with QIAquick PCR Purification Kit (Qiagen). The labelled 
complementary RNA (cRNA) was prepared with Illumina TotalPrep RNA 
Amplification Kit (Ambion) and hybridised to Illumina HumanWG-6_V2_0_R2 
BeadChip expression arrays (lllumina). The quality of the RNA and labelled 
cRNA was assessed with the 2100 Bioanalyzer (Agilent). The samples were 
collected from three independent experiments. The raw signal intensities were 
normalised with the rank-invariant normalisation method implemented in the 
BeadStudio Gene Expression Module v3.3.7 (Illumina). Genes with an absolute 
differential score above 13, which corresponds to a p-value threshold of 0.05  
(–10 × log100.05), and an absolute fold change cut-off of 2 were considered to be 
differentially expressed. Gene and sample groups were analysed with unsuper-
vised hierarchical clustering by using Manhattan distance and complete linkage 
criteria as implemented in the Multi Experiment Viewer software version 4.0 
(http://mev.tm4.org/). The tissue specificity of the differentially expressed genes 
was analysed using the RefSeq and Unigene gene lists in the TiGER database 
(Liu et al., 2008). The statistical significance of the enrichment of TRA genes 
among differentially expressed genes was assessed with chi-squared test by 
considering the number of all genes (19646) and the fraction of TRA genes 
(5524) found on both Illumina arrays and in the TiGER database (p-value thres-
hold – 0.05). The genomic gene clusters were analysed with the CROC software 
with default options except that the minimum number of interesting genes in a 
cluster was set to two (Pignatelli et al., 2009). The statistical significance of the 
genomic clustering was calculated as follows: 1) 10,000 random gene sets size-
matched to the observed differentially expressed gene list were generated based 
on the human genome build 36.1/hg18 provided by the National Center for 
Table 2. Continuation
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Biotechnology Information (NCBI); 2) each random gene set was analysed for 
genomic clustering with the CROC software; 3) the number of occurrences 
where the number of gene clusters found in random gene sets was equal or 
greater than the number of observed gene clusters was divided by the number of 
random gene sets to give a p-value. 
 
 
4.11. GST pull-down assays 
The glutathione S-transferase (GST)-tagged proteins were expressed in the 
NovaXG E.coli strain (Novagen) by addition of 0.8 mM isopropyl β-D-1-
thiogalactopyranoside and 0.2 mM ZnCl2. The proteins were purified using 
Glutathione SepharoseTM 4B (GE Healthcare) as described in (Org et al., 2008). 
Sepharose-bound proteins (2–10 µg) were incubated for 4 h at 4 °C with 20 µg 
calf thymus histones (Sigma-Aldrich) in binding buffer containing 50 mM Tris–
HCl pH 7.5, 1M NaCl, 1% NP-40, 0.5 mM EDTA and 1× protease inhibitor 
cocktail (Sigma-Aldrich). The samples were washed with 8 × 1 ml binding 
buffer and run on 15% SDS-PAG for 20 min at 100 V and followed by 
Coomassie G-250 staining. 
 
 
4.12. Chromatin immunoprecipitation 
ChIP experiments were performed using 107 cells per experiment according to a 
previously described protocol with slight modifications (Dahl and Collas, 
2007). Briefly, the uninduced and doxycycline-induced AIRE-Tet cells, either 
untreated or treated with etoposide, were cross-linked with 1% formaldehyde 
for 10 min at room temperature, and the formaldehyde was quenched by the 
addition of glycine to a final concentration of 0.125 M. Cells were lysed in 
200 μl lysis buffer (50 mM Tris-HCl, pH 8, 10 mM EDTA, 1% SDS, 1× Halt 
Protease Inhibitor Cocktail, Thermo Scientific). The samples were diluted 
10 times in RIPA buffer containing 1× Halt Protease Inhibitor Cocktail. Soni-
cation was performed with the Diagenode Bioruptor for 15 min using 30 sec on-
off cycles at a high voltage setting. After chromatin preparation, ChIP was 
performed with the IP-Star Compact Automated System (Diagenode) using the 
ChIP Direct method, which requires antibody-coated magnetic beads that are 
added to the sheared chromatin (the protocol and magnetic beads are from 
Diagenode). ChIP-grade antibodies against high mobility group B1 (HMGB1), 
γH2AX and histone H1 are listed in Table 3. The ChIP signals were measured 
by qPCR and the values were log-transformed, standardised and scaled according 
to the procedure described in (Willems et al., 2008). Experimental groups were 
compared with the two-sample t-test implemented in R statistical software. 
Primers for the ChIP DNA analysis are listed in Table 5. 
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Table 5. List of ChIP primers used in the study. 
Region Primer name Sequence 
S100A8 promoter ch_SA81_F TGTGCTGGGTCCCCAATGGC 
 ch_SA81_R GCTGCTTGGGGTCCCTCTGC 
S100A8 control ch_SA81_con_F TGGCTTTGGTCTCGCCGTCTAAGTAA 
 ch_SA81_con_R TGGTGGGTTCAAGGTGCACTGTAGAT 
IVL promoter ch_IVL_F CCAATCCTTTAGATATGGTACACAG 
 ch_IVL_R TCCCCAGGTCTCTGGTTCTT 
IVL control ch_IVL_con_F TGTTTGTGTTGTGCAAGGCCGAGA 
 ch_IVL_con_R AGGAACATTTTGTCAGGCCAAGGCT 
PSMD4 promoter ch_PSMD4_F GATAGTCCCGGGTTACCAC 
 ch_PSMD4_R TGTAGCTAAAGACAGACCCG 
GAPDH promoter ch_GAPDH_F CCCGTCCTTGACTCCCTAGT 
 ch_GAPDH_R GGGGGAAGGGACTGAGATT 
 
 
4.13. Formaldehyde-assisted isolation  
of regulatory elements 
The FAIRE experiments were done with the uninduced and doxycycline-
induced AIRE-Tet cells that were either left untreated or treated with etoposide. 
The cells were grown on 10 cm tissue culture plates to near full confluence, 
which corresponds to ~107 cells. The cells were cross-linked with 1% 
formaldehyde for 10 min at 22 °C followed by quenching the cross-linking 
reaction by adding glycine (final concentration 0.125 M) to the medium. The 
cells were lysed with 200 µl of lysis buffer (50 mM Tris-HCl (pH 8), 10 mM 
EDTA, 1% SDS, and 1× Halt protease inhibitor mixture (Thermo Scientific)). 
Cellular debris was removed by spinning the lysates at 20,000 × g for 10 min at 
4 °C. The input samples (10% of lysates) were treated with 10 µg of DNase-free 
RNase A (Thermo) for 30 min at 37 °C, followed by 10 µg of proteinase K 
incubation overnight at 65 °C. The DNA from the remaining lysates and the pro-
teinase K-treated input samples was prepared with standard phenol-chloroform 
extraction and additionally purified with a Qiagen PCR purification kit. 
 
 
4.14. Chromatin conformation capture 
Uninduced and doxycycline-induced AIRE-Tet cells were processed according 
to the protocol in (Hagège et al., 2007), except that the Sau3AI restriction 
enzyme (purchased from Thermo Fisher) was used in the DNA digestion step. 
The chromatin interactions were calculated as the ratio of the qPCR signal in 
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the doxycycline-induced sample relative to the signal in the uninduced control 
sample. The anchor region was selected based on the results of high throughput 
sequencing of the FAIRE samples. The 3C signals were measured by qPCR, 
and the values were log-transformed, standardised, and scaled according to the 
procedure described in (Willems et al., 2008). Statistical significance of the log2 
fold change was assessed with a one-sample t-test implemented in R statistical 
software. Primers for the 3C qPCR analysis were designed according to the 
guidelines in (Hagège et al., 2007) and are listed in Table 6. 
 
Table 6. The list of 3C primers used in the study. 
Region Primer name Sequence 
CTCF site 10 
forward 
3c_anchor_site10_F CTCCCCAAGCTCTAACAACCAA 
CTCF site 10 
reverse 
3c_anchor_site10_R CTCTTTGCACCTCAGTCCTCTC 
CTCF site 1 3c_site1_F GACTTAGAGGCTTCAGTCATCATCC 
CTCF site 2 3c_site2_F TAAGGAGCAAGGAGACCAGGAG 
CTCF site 3 3c_site3_F CTTCCCTTGGCCATTTCCCA 
CTCF site 4 3c_site4_F CAAATTCCCGTCCTCAAGCAATC 
CTCF site 5 3c_site5_F GAAATTAGCCTCACTGAGTCACTGT 
CTCF site 6 3c_site5_R GAGCTGGGAAATAACACTCACACTA 
CTCF site 7 3c_site7_F AGTTGGTAGGAGCGACTTTAGAAAT 
CTCF site 8 3c_site8_F CCTATGACCCTTAGCCTCTCTGAG 
CTCF site 9 3c_site9_F AGATTGTGGTCTTATGTCAGGTCAA 
CTCF site 11 3c_site11_R TGGTGGACAGGAGGGAAGTG 
CTCF site 12 3c_site12_F TTTGCTAAGGAAGTGGAGGTGGA 
CTCF site 13 3c_site13_R CTTGTGGAAACTCTGAGAACTGCAT 
CTCF site 14 3c_site14_R CGGAGAACTGCTTCACAATCTTTAA 
CTCF site 15 3c_site15_R AAAATGAAGCGACTTGTCCAGG 
CTCF site 16 3c_site16_F CACATATTCCCAACAACTCTGCAAG 
CTCF site 17 3c_site17_F TGGAAGTAACTGTCAGAGAGAGCT 
CTCF site 18 3c_site18_F AAAATATAGAAATATGGGGCCGGGC 
CTCF site 19 3c_site19_F CACTTATTCCCAACAACTCTGCAAG 
CTCF site 20 3c_site20_F ACAAACAAACTCAGGCTGTAAAGAC 
CTCF site 21/22 3c_site21/22_F GTGCAGCTAGATGGTCAGTCC 
CTCF site 23 3c_site23_R GCCAATTTAGATTTACCTGCCCC 
CTCF site 24 3c_site24_R AGTGTAAACAACGGTGCTTTTAACA 
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4.15. High-throughput sequencing and data analysis 
The FAIRE-seq libraries were prepared following the Illumina Truseq ChIP sample 
preparation instructions and sequenced on an Illumina HiSeq 2000 machine to 
produce 100 bp paired-end reads. The quality control of the sequencing results was 
performed with the FastQC software (http://www.bioinformatics.babraham.ac.uk/ 
projects/fastqc/). Sequencing adapter sequences and low quality base calls 
(Phred score < 30) were removed with Trim Galore! (https://www.bioinformatics. 
babraham.ac.uk/projects/trim_galore/). The remaining paired-end reads were 
mapped to the human genome build 37/hg19 povided by the NCBI with 
bowtie2 in “local” mode (Langmead and Salzberg, 2012). Properly paired reads 
with a mapping quality of > 30 were used for detecting differentially accessible 
chromatin regions with the csaw package for R statistical software (Lun and 
Smyth, 2016). The differentially accessible regions were annotated with the 
ChIPseeker R package (Yu et al., 2015). The statistical significance of overlap 
between different sets of genomic intervals was assessed with the Geno-
metriCorr package for R statistical software (Favorov et al., 2012).  
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5. RESULTS 
5.1. The post-translational acetylation  
of the AIRE protein by the transcription  
co-activator protein p300 (Study I) 
Previous studies had established that CBP was a major interaction partner for 
AIRE (Pitkänen et al., 2000). CBP is a well-known transcription co-activator 
that in addition to mediating various protein-protein interactions possesses 
acetyltransferase activity. Interestingly, the human genome encodes a paralog of 
CBP, which is named p300 and has both redundant and unique functionality 
compared to CBP (Vo and Goodman, 2001). These observations led to the 
investigation of the post-translational acetylation of AIRE by CBP or p300 by a 
series of overexpression and immunoprecipitation assays. 
The expression plasmids of CBP, p300, p300DY (an acetyltransferase-
deficient form of p300) and PCAF were transfected into the stable AIRE-
expressing HEK-AIRE cell line (Org et al., 2008). Immunoprecipitation was 
performed with anti-AIRE antibody and the signal of acetylated lysines was 
detected with anti-acetyl lysine specific antibody. These steps were also per-
formed with HEK-AIRE cells that were transfected with YFP-encoding expres-
sion plasmid, which served as a negative control experiment, and with HEK-
AIRE cells that were treated with Trichostatin A (TSA), a compound that is 
known to inhibit protein deacetylase activity, thereby increase the overall level 
of protein acetylation and could act as a positive control in this experimental 
setup. The ectopic expression of CBP, p300, PCAF, and the TSA treatment 
resulted in a strong total protein acetylation signal, while the ectopic expression 
of p300DY, similarly to YFP, did not show any significant increase in the 
fraction of acetylated proteins (Figure 2A, input lanes). 
Furthermore, a distinct acetylation signal was visible at the molecular weight 
corresponding to AIRE protein after the overexpression of p300, which was 
weakly present or undetectable in other conditions (Figure 2A, IP lanes). 
These findings encouraged to perform a mass-spectrometric analysis to 
compare the protein extracts from HEK-AIRE cells transiently transfected with 
p300 or CBP with protein extracts from untransfected cells. Altogether 12 
acetylated lysine residues (50% of all lysine residues in AIRE protein) were 
identified from which many were detectable only after the overexpression of 
p300 (Figure 2B, Table 7). 
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Figure 2. The AIRE protein is the substrate for acetylation by p300. (A) Detection of 
acetylated AIRE in HEK-AIRE cells after overexpression of CBP, PCAF, p300, 
p300DY or TSA treatment. Cells transfected with YFP were included as negative 
control. AIRE was immunoprecipitated with anti-AIRE 6.1 antibody (α-AIRE) and a 
control IP was performed with normal goat serum IgG (IgG) for every sample. 
Immunocomplexes were resolved on SDS-PAG and acetylated AIRE was detected with 
anti-AcLys antibody (α-AcLys) in western blot. The arrow indicates the position of 
AIRE. Western blot with anti-AIRE 6.1 antibody was used to determine the presence of 
the AIRE protein. The 2 % input refers to the amount of whole cell lysate loaded onto 
the gel. (B) Protein domain diagram displaying all acetylated lysines in AIRE according 
to the mass-spectrometric analysis (CARD, caspase recruitment domain; NLS, nuclear 
localisation signal; SAND, the Sp100, AIRE-1, NucP41/P75 and DEAF1 domain; PHD, 
plant homeodomain zinc finger). The figure is adapted from Study I. 
 
Table 7. Acetylated lysine residues in the AIRE protein determined by mass-spectro-
metry. Roman numerals refer to experimental replicates. 
 
K
11
4 
K
12
0 
K
13
1 
K
15
9 
K
16
4 
K
16
5 
K
22
1 
K
22
2 
K
24
3 
K
24
5 
K
25
3 
K
25
9 
AIRE I         +  + + 
AIRE II         +  +  
AIRE + p300 I + + + + +  +    +  
AIRE + p300 II + +   + +  + + + + + 
AIRE + CBP   +    + + +  + + 
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expression of p300 or CBP suggesting that AIRE is also a substrate for endo-
genous acetyltransferases. 
Three acetylated lysines, K114, K120, and K131, were found in the known 
AIRE NLS while the acetylated residues K159, K164, and K165 were mapped 
to putative bipartite NLS (Ilmarinen et al., 2006; Saltis et al., 2008) (Figure 2B). 
The remaining six modified residues, K221, K222, K243, K245, K253, and 
K259 were located in the SAND domain, which has been characterised as a 
DNA binding domain in many other proteins, but not in AIRE (Figure 2B). In 
conclusion, these results show that AIRE can be acetylated by ectopically 
expressed p300 and CBP as well as endogenous acetyltransferases in HEK293 
cells. 
 
 
5.2. The effect of acetylation site mutations in the AIRE 
SAND domain on protein localisation (Study I) 
The SAND domain is a DNA binding domain in several transcriptional regu-
lators (Bottomley et al., 2001; Isaac et al., 2006; Jensik et al., 2014). Although 
DNA binding by AIRE SAND domain has been disputable, the acetylation of 
almost all lysines in AIRE SAND domain prompted to ask whether it has any 
effect on the localisation of the AIRE protein and its function as a transcriptio-
nal regulator. Subsequent experiments included a set of AIRE expression 
plasmids where the most frequently acetylated lysines in the AIRE SAND 
domain – K243 and K253 together with K245 in-between – were substituted 
with either glutamine, which has a neutral charge mimicking an acetylated 
position, or arginine, which preserves the positive charge similar to an un-
modified lysine residue (Choudhary et al., 2009; Hecht et al., 1995; Li et al., 
2002; Wang and Hayes, 2008). The expressed sets of AIRE proteins were 
named AIRE Q and AIRE R mutants, respectively. 
Immunofluorescence analyses have established that the AIRE protein forms 
punctate structures in the cell nucleus, which have been named AIRE nuclear 
bodies, and that AIRE colocalises with the transcriptional coactivator CBP 
(Pitkänen et al., 2005). In this study, we showed that AIRE also colocalises with 
endogenous p300, a paralog of CBP, in HEK-AIRE cells (Figure 3A). 
The K-to-Q or K-to-R mutations in the AIRE SAND domain did not disturb 
the colocalisation of AIRE and p300. However, the AIRE Q mutants con-
centrated into fewer but larger nuclear bodies while the AIRE R mutants formed 
nuclear bodies characteristic of wild-type AIRE, both in terms of number and 
size (Figure 3B and C). 
 
 
The overexpression of CBP resulted in fewer acetylated lysines, although all of 
them overlapped with the sites found in at least one sample with p300 
overexpression. Altogether 3 sites were acetylated in cells without any ectopic 
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Figure 3. Wild-type and mutated AIRE colocalise with endogenous p300, but display 
differences in the size and number of nuclear bodies in HEK293 cells. (A) Colo-
calisation of stably transfected wild-type AIRE and endogenous p300 in HEK-AIRE. 
(B) Colocalisation of transiently transfected AIRE Q mutants and endogenous p300 in 
HEK293 cells. (C) Colocalisation of transiently transfected AIRE R mutants and 
endogenous p300 in HEK293 cells. AIRE and p300 were detected with anti-AIRE and 
anti-p300 antibodies, respectively. Scale bar corresponds to 10 μm. The figure is 
adapted from Study I. 
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5.3. The effect of overexpression of p300 on AIRE protein 
stability and localisation (Study I) 
Lysine acetylation is known to prolong protein half-life by preventing lysine 
polyubiquitylation, which is recognised by the proteasomal system as a protein 
degradation signal (Glozak et al., 2005). An earlier study had shown that AIRE 
is ubiquitylated and that the inhibition of the proteasome increases the AIRE 
protein level in the nucleus (Akiyoshi et al., 2004). To test whether the 
acetyltransferase activity of p300 could affect the AIRE protein levels, HEK-
AIRE cells were transfected with either wild-type or acetyltransferase-deficient 
p300 and treated with the protein translation inhibitor cycloheximide. 
The analysis of the AIRE protein abundance in the cell lysates at several time 
points showed that the AIRE protein is stabilised only after the overexpression 
of the wild-type p300, while the level of AIRE in cells expressing p300DY or 
YFP (negative control) declined about 50% in 6 h (Figure 4A). 
 
Figure 4. Overexpressed 
p300 stabilises AIRE and 
localises to AIRE nuclear 
bodies in HEK-AIRE cells. 
(A) The stability of AIRE 
after the overexpression of 
p300 in HEK-AIRE cell 
line. Cells transfected with 
p300, p300DY or YFP were 
incubated with translation 
inhibitor cycloheximide and 
lysed at different time 
points. Lysates were subjec-
ted to western blotting and 
AIRE signal intensities were 
normalised to GAPDH ex-
pression. The graphs repre-
sent three independent ex-
periments ± standard error 
of the mean (SEM). (B) Co-
localisation of AIRE with 
wild-type p300 or the acetyl-
transferase-deficient p300DY 
in HEK-AIRE cells. AIRE 
and p300 were detected 
with anti-AIRE (green) and 
anti-p300 antibodies (red), 
respectively. Scale bar cor-
responds to 10 μm. The fi-
gure is adapted from 
Study I. 
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Interestingly, the overexpression of p300, and not p300DY, resulted in larger 
and fewer AIRE nuclear bodies resembling the localisation of the AIRE Q 
mutants (Figure 4B). 
 
 
5.4. The impact of acetylation site mutations and  
p300 overexpression on the transcriptional  
activity of AIRE (Study I) 
A series of luciferase activation assays and expression analyses of endogenous 
genes by quantitative PCR were performed to test whether the transcriptional 
activity of AIRE is altered alongside with the observed changes in protein 
localisation and stability due to p300 overexpression or mutations in the AIRE 
SAND domain. In these experiments, the expression of two known AIRE-
dependent genes – involucrin (IVL) and S100 calcium binding protein A8 
(S100A8) (Derbinski et al., 2005; Liiv et al., 2008; Org et al., 2009) – was used 
to assess how AIRE activates its endogenous targets in HEK293 cells. For the 
luciferase activation assays, a reporter plasmid containing the IVL gene 
promoter upstream of the luciferase coding sequence was used. 
Both endogenous and reporter gene activation assays showed that the ectopic 
expression of p300 with or without its acetyltransferase activity did not signi-
ficantly influence the AIRE-dependent gene activation in HEK293 cells (Figure 
5A and B). 
However, the luciferase activity after the overexpression of AIRE Q mutants 
decreased 1.5–3.4 times compared to the wild-type protein (Figure 5C), while 
the AIRE R mutants retained their transcriptional activity at levels comparable 
to that of wild-type AIRE (Figure 5D). 
The K-to-Q mutations had an even more drastic effect on the expression of 
endogenous AIRE target genes by reducing the transactivation of AIRE at least 
5 times (Figure 5E). Again, the gene activation mediated by the AIRE R 
mutants was similar to that of wild-type AIRE (Figure 5F). These data suggest 
that the acetylation of the lysine residues within the AIRE SAND domain 
contributes to the transcriptional activity of AIRE. Furthermore, the similar 
results of wild-type and AIRE R mutants indicated that AIRE might be de-
acetylated prior to the activation of AIRE-dependent genes. 
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Figure 5. The acetylation site mutations, but not the overexpression of p300, affect the 
kiirustasime rongiletranscriptional activity of AIRE in HEK293 cells. (A) Luciferase 
reporter gene activity after the overexpression of AIRE with wild-type or acetyl-
transferase-deficient p300 (p300DY). HEK293 cell lysates were assayed for luciferase 
expression driven by the AIRE target gene IVL promoter in the pBL-INV reporter 
plasmid 48 h after transfection with AIRE. The results represent means of 3 inde-
pendent experiments ± SEM. (B) The expression of endogenous AIRE target genes IVL 
and S100A8 after the overexpression of AIRE with wild-type or acetyltransferase-
deficient p300 (p300DY). The mRNA was extracted from HEK293 cells 48 h after 
transfection. The results represent means of 5 independent qPCR experiments ± SEM. 
(C) and (D) Luciferase reporter gene activity after the overexpression of AIRE Q and R 
mutants, respectively. HEK293 cell lysates were assayed for luciferase expression 
driven by the AIRE target gene IVL promoter in the pBL-INV reporter plasmid 48 h 
after transfection with AIRE. Expression of wild-type and mutant AIRE proteins is 
shown below the graphs. (E) and (F) The expression of endogenous AIRE target genes 
IVL and S100A8 after the overexpression of AIRE Q and R mutants, respectively. The 
mRNA was extracted from HEK293 cells 48 h after transfection. (C–F) Luciferase 
assay and qPCR results are presented as means of two independent experiments ± SEM. 
NC, negative control sample (cells transfected with the empty expression vector 
pcDNA3.1B(–)Myc/His). The figure is adapted from Study I. 
 
 
5.5. The effect of the K243/K253Q SAND domain  
mutation on the expression profile of AIRE  
target genes in HEK293 cells (Study I) 
The results with the select target genes prompted to investigate whether the 
mutations at the acetylation sites in the AIRE SAND domain can interfere with 
the genome-wide expression of AIRE-dependent genes. To address this question, 
an additional HEK293 cell line was generated that expressed the AIRE.K243/ 
253Q mutant protein. The mRNA expression profile of the HEK-AIRE.K243/ 
253Q cell line was compared to the previously characterised HEK-AIRE and 
HEK-YFP (control) cell lines in Illumina array analysis (Org et al., 2008). 
The differential expression analysis revealed that 243 genes were signi-
ficantly upregulated in the HEK-AIRE cells compared to the control cell line. In 
contrast to the expectation that the HEK-AIRE.K243/253Q cells have a similar 
transcriptional program to HEK-YFP cells, 190 upregulated genes was detected 
of which 81 genes were shared with the HEK-AIRE cells (Figure 6A). 
However, the fold changes of the differentially expressed genes in the 
presence of AIRE.K243/253Q seemed to be weaker, which was also confirmed 
by qPCR on a subset of differentially expressed genes (Figure 6B). 
The genes up-regulated in HEK-AIRE or HEK-AIRE.K243/253Q cells were 
mostly expressed at a very low or undetectable level in HEK-YFP cells (ave-
rage signal intensity was 176 for AIRE and 133 for K243/253Q). These findings 
are consistent with a previous report, which concluded that AIRE activates 
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genes with low initial expression and represses highly expressed genes (Org et 
al., 2009). In concordance with earlier studies, both AIRE and AIRE.K243/ 
253Q-regulated genes were enriched for TRA genes and based on their location 
in the genome belonged to chromosomal gene clusters (Derbinski et al., 2005; 
Johnnidis et al., 2005; Org et al., 2009) (Table 8). 
Taken together, the data show that the AIRE Q double mutant still retains 
transactivation activity, but targets a different set of genes than the wild-type 
protein. 
 
 
 
Figure 6. Acetylation mimicking mutations change the set of AIRE-regulated genes. 
(A) Venn diagram showing gene numbers activated or repressed by either wild type 
AIRE (dark grey) or AIRE.K243/253Q (white), and their overlap (light grey). 
(B) Relative mRNA levels of genes activated by wild-type AIRE (top row, BAI3, 
CDH11, and IFI16), AIRE.K243/253Q (middle row, CHST13, PAPLN, and CXCR7) 
and both (bottom row, CLDN1, LY6G6D, and LPL). The results are presented as mean 
of three independent qPCR experiments ± SEM. NC, negative control (HEK-YFP cell 
line). The figure is adapted from Study I. 
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Table 8. Enrichment of tissue-specific genes and chromosomal clustering of AIRE-
regulated genes. 
 Upregulated Downregulated   
 Tissue-
specific 
Total p-value Tissue-
specific 
Total p-value 
AIRE 62 136 5.82E-06 9 28 0.63 
AIRE. K243/253Q 40 97 0.004 9 19 0.06 
Overlap 31 66 0.0007 6 13 0.15 
 Upregulated Downregulated 
 Genes Clusters p-value Genes Clusters p-value 
AIRE 214 21 0.017 43 3 0.019 
AIRE.K243/253Q 168 16 0.007 31 2 0.034 
Overlap 73 6 0.005 13 1 0.053 
 
The AIRE protein has two PHD-type zinc finger domains, named accordingly 
PHD1 and PHD2, and both have been linked to the role of AIRE as a transcrip-
tional regulator. The PHD1 domain is known to mediate protein-protein inter-
actions with the core nucleosome component histone H3 and mutations that 
abolish this interaction have been found in APS1 patients (Koh et al., 2008; Org 
et al., 2008). In addition, the AIRE PHD2 mutation C446G has been discovered 
in APS1 patients (Wolff et al., 2007). The AIRE PHD2 domain has been shown 
to participate in gene activation when tethered to the DNA-binding Gal4 domain 
(Meloni et al., 2008; Uchida et al., 2004). More recently, transgenic mice 
expressing AIRE that lacks the PHD2 domain displayed weaker expression of 
the AIRE-dependent TRAs (Yang et al., 2013). However, the molecular events 
that are associated to the mutations in the AIRE PHD2 and lead to disease have 
not been described before. 
Study II focused on the identification of interaction partners that require 
either of the intact AIRE PHD domains to form protein complexes with AIRE. 
In the first part of the study, the structure of the AIRE PHD2 was modelled, 
which revealed the network of Zn2+ ion-coordinating (including the amino acid 
C446) and hydrophobic interactions that stabilise the protein domain (Study II, 
Figure 1). The APS1-associated mutation C446G disrupts metal binding and 
destroys the structure of PHD2 domain (Study II, Figure 1D). Furthermore, 
immunofluorescence analyses showed that the loss of the PHD2 domain causes 
the majority of AIRE to retain in the cytosol (Figure 7A) where it forms 
insoluble aggregates, which are difficult to detect by western blot (Figure 7B). 
In contrast, the mutations V301M and D297A in PHD1 domain do not affect 
the subcellular localisation of AIRE (Figure 7A and B). 
5.6. The role of the AIRE PHD2 domain mutation C446G  
in AIRE-dependent transcriptional regulation and  
protein-protein interactions (Study II) 
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Figure 7. The effects of PHD finger mutations on AIRE subcellular localisation, AIRE-
dependent target gene expression and histone binding. (A) AIRE staining (green) in 
HEK293T cell line transfected with expression plasmids for wild-type AIRE (WT), 
AIRE V301M, AIRE D297A and AIRE C446G. The nucleus was stained with Hoechst 
33258 (blue). (B) Western blot of HEK293T cell lysates transfected with expression 
plasmids for wild-type AIRE (WT) and PHD finger mutants. The amount of recovered 
AIRE protein (anti-AIRE antibody, Everest Biotech) in the cytosolic and nuclear 
extracts as well as after chromatin solubilisation (mChIP) was compared to tubulin 
(anti-tubulin antibody, Sigma-Aldrich) and histone H3 (anti-histone H3 antibody, 
Abcam). CTL, negative control sample (cells transfected with the empty expression 
vector pcDNA3.1B(–)Myc/His). (C) A comparison of the transcriptional activity of 
wild-type AIRE and AIRE harbouring PHD1 mutations V301M and D297AV or the 
PHD2 mutation C446G. Relative expression level of AIRE-regulated genes IVL, 
S100A8 and HBG2 genes and AIRE-independent genes BAT2 and S100A10 was 
measured 48 h after transfection. The results are presented as means of two independent 
qPCR experiments ± SEM. Cont, negative control (cells transfected with the empty 
expression vector pcDNA3.1B(–)Myc/His). (D) The AIRE PHD2 mutant binds histone 
H3 as efficiently as wild type AIRE. The interaction between calf thymus histones and 
GST alone (GST), GST-AIRE (AIRE) or GST-AIRE.C446G (AIRE C446G) was 
visualised by Coomassie G-250 staining. The figure is adapted from Study II. 
 
 
 
Decidedly, the structural aberrations related to the mutation C446G strongly 
reduced the expression of AIRE target genes, such as IVL, S100A8 and the 
haemoglobin subunit gamma 2 (HBG2) (Figure 7C). The drop in gene acti-
vation was comparable to the one seen after the ectopic expression of AIRE 
carrying the PHD1 mutations D297A or V301M (Figure 7C), the former 
affecting binding to histone H3 and the latter potentially disrupting additional 
protein-protein interactions as previously reported (Koh et al., 2008; Org et al., 
2008). Interestingly, in GST pull-down assays with full-length AIRE protein, 
the C446G mutation did not affect the binding to histone H3 (Figure 7D) 
suggesting that the structural integrity of PHD2 is not required for the 
interaction of AIRE with histone H3, which is in agreement with published data 
on peptide pull-down assays with AIRE deletion mutants (Koh et al., 2008). 
In summary, the results suggest that the C446G mutation in AIRE PHD2 
alters the protein structure and subcellular localisation preventing the activation 
of the expression of AIRE target genes. However, unlike mutations in the 
PHD1, the C446G mutation in AIRE PHD2 does not influence binding to 
histone H3, indicating that the two PHD zinc fingers mediate distinct protein-
protein interactions. 
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5.7. The AIRE-dependent changes in chromatin  
accessibility and conformation near AIRE target  
genes and beyond (Study III) 
The protein structure of AIRE, which consists of several domains that are 
required to interact with chromatin- and transcription-related proteins, and the 
ability to activate thousands of silenced genes in any cell type where AIRE is 
introduced raises the question of what happens to the underlying chromatin 
landscape during this dramatic shift in the cells’ transcriptional program. 
Accordingly in Study III, the genome-wide changes in gene expression were 
integrated with the analyses of chromatin-related molecular events by taking 
advantage of the AIRE-Tet cell line where AIRE expression can be induced by 
adding doxycycline to the cells (Liiv et al., 2012). Previously, it was shown that 
the inhibition of the religation activity of topoisomerase 2 (TOP2) by etoposide 
could trigger the upregulation of many AIRE-dependent genes (Abramson et 
al., 2010). Therefore, etoposide treatment was included as one of the experi-
mental conditions in the study. 
In Study III, the chromatin immunoprecipitation analyses revealed that the 
AIRE-expressing AIRE-Tet cells, especially after etoposide treatment become 
enriched for the histone H2A variant γH2AX at the AIRE target gene promoters 
(Figure 8A).  
 
 
Figure 8. 
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Figure 8. Inhibition of TOP2 with etoposide increases the occurrence of 
double-stranded DNA breaks and facilitates H1/HMGB1 exchange in AIRE 
target gene promoters. (A) Assessment of DNA breaks as measured by the 
enrichment of the histone γH2AX in AIRE-dependent S100A8 and IVL gene 
promoters and distal control regions in the uninduced/untreated (Ctrl), 
doxycycline-induced (Dox), doxycycline-induced/etoposide-treated (Dox+Etop), 
and etoposide-treated (Etop) AIRE-Tet cells using qPCR. The box and whiskers 
plots show the median and interquartile range of log2-transformed data from 
three independent experiments. Whiskers cover data points within a 1.5 × inter-
quartile range. Statistical significance was assessed by two-sample t test (*, p < 
0.05; **, p < 0.01). (B) Analysis of H1 and HMGB1 enrichment at AIRE target 
gene (S100A8 and IVL) and AIRE-independent gene (PSMD4 and GAPDH) 
promoters in Ctrl, Dox, Dox+Etop, and Etop AIRE-Tet cells by qPCR. IgG was 
used as a negative control for ChIP experiments. The box and whiskers plots 
show the median and interquartile range of log2-transformed data from five in-
dependent experiments. Whiskers cover data points within a 1.5 × interquartile 
range. Statistical significance was assessed by two-sample t test (*, p < 0.05; **, 
p < 0.01; ***, p < 0.001). The figure is adapted from Study III. 
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Notably, the presence of histone γH2AX signals DNA damage, including DNA 
breaks that are generated by TOP1 and TOP2 to relieve DNA supercoiling that 
results from the DNA or RNA polymerase activity (Lowndes and Toh, 2005). 
The same set of promoter regions underwent an exchange of the linker histone 
H1, which is considered to be a constituent of silenced chromatin, for the 
HMGB1 (Figure 8B), an indicator of a more relaxed and accessible chromatin 
(Cato et al., 2008). These results with the select AIRE target gene loci sug-
gested that AIRE can influence the chromatin structure and prompted to test 
whether the presence of AIRE coincides with genome-wide changes in chro-
matin accessibility. 
The genome-wide alterations in chromatin structure were analysed by 
formaldehyde-assisted isolation of regulatory elements (FAIRE) coupled with 
high-throughput sequencing, which allows the detection of open chromatin 
regions (Giresi et al., 2007). Approximately 1000 and 1900 genomic regions in 
either untreated or etoposide-treated AIRE-expressing AIRE-Tet cells (Dox and 
Dox+Etop, respectively) were found to be differentially accessible compared to 
the uninduced/untreated control AIRE-Tet cells (Ctrl). In contrast, cells only 
treated with etoposide (Etop) did not have any FAIRE peaks that were diffe-
rentially accessible compared with the control AIRE-Tet cells. Interestingly, 
more than 90% of the FAIRE peaks in Dox and Dox+Etop cells apparently lost 
their open conformation, which mostly occurred at gene promoters, as assessed 
by the overlap between the FAIRE peaks and genic/intergenic annotations 
(Figure 9A). 
However, only a small fraction out of all differentially accessible regions in 
Dox and Dox+Etop cells were close to AIRE-dependent genes (Figure 9B). 
Instead, a large proportion of differentially accessible regions in Dox and 
Dox+Etop cells were detected at HEK293-specific binding sites of the 
chromatin architectural protein CTCF (Figure 9C). Earlier studies have shown 
that the chromatin loops formed by CTCF can determine the expression genes 
within and outside of the boundaries of those structures (Nora et al., 2012; Zuin 
et al., 2014; Tark-Dame et al., 2014). Furthermore, disruption of the CTCF 
loops can result in misregulation of transcription leading to disease (Katainen et 
al., 2015). The finding that chromatin accessibility changes at CTCF sites 
prompted to test whether CTCF-mediated chromatin contacts could be 
remodelled in the presence of AIRE. 
The study concentrated next on a 310-kb genomic region on chr19 containing 
the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) cluster 
genes CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, and 
CEACAM21, which are coexpressed with AIRE in human medullary thymic 
epithelial cells (Cloosen et al., 2007; Pinto et al., 2013). In AIRE-Tet cells, 
several of the CEACAM genes were differentially expressed in Dox and 
Dox+Etop cells, and the differentially accessible FAIRE peaks overlapped with 
CTCF sites within and flanking the gene cluster (Figure 10A).  
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Figure 9. FAIRE-seq reveals AIRE-dependent changes in chromatin accessibility in 
AIRE-Tet cells. (A) Percentages of FAIRE peaks that overlap with genic and intergenic 
regions in Dox and Dox+Etop AIRE-Tet cells relative to Ctrl. The x-axis labels refer to 
the FAIRE peaks that show either loss or gain of chromatin accessibility (Closed and 
Open, respectively). The numbers of the peaks are shown in brackets. The overlaps 
between the peaks and promoters up to 3 kb from transcription start site were assessed 
with the relative distance test implemented in the GenometriCorr package for R 
statistical software. (B) Distance between differentially expressed genes and closest 
FAIRE peaks in Dox and Dox+Etop AIRE-Tet cells. The statistical analysis did not 
determine significant overlap between the genomic regions. (C) Differentially enriched 
FAIRE peaks show a strong enrichment of CTCF sites in AIRE-Tet cells both with Dox 
and Dox+Etop treatment. Numbers of FAIRE peaks in the overlap are shown on the 
bars. The statistical significance of the overlaps between the FAIRE-seq peaks and 
HEK293-specific CTCF sites was assessed with the relative distance test implemented 
in the GenometriCorr package for R statistical software. The figure is adapted from 
Study III. 
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The potential impact of AIRE on CTCF binding and CTCF- mediated chromatin 
interactions was investigated by chromosome conformation capture (3C) assay, 
which combines protein cross-linking and proximity ligation of DNA to detect 
long-range chromatin interactions between genomic loci (Hagège et al., 2007). 
The FAIRE peak that overlapped with the CTCF binding site 10 between 
CEACAM5 and CEACAM7 genes (Figure 10B), and became less accessible 
after AIRE induction, was set as the anchor region for the 3C experiments. The 
chromatin interactions between the anchor region and the remaining 23 CTCF 
sites within the CEACAM locus were analysed by qPCR using primers that 
corresponded to Sau3AI-specific restriction fragments that either overlapped or 
flanked the CTCF sites. The 3C signal from Dox cells was compared to the 
uninduced AIRE-Tet cells. The results showed that in AIRE-expressing cells, 
the anchor CTCF site formed stronger chromatin contacts with sites 1 and 4 
flanking CEACAM21 and with site 12 near CEACAM5. In addition, contacts 
with sites 3 and 19 close to the CEACAM21 and CEACAM3 genes, respectively, 
became significantly weaker in AIRE-expressing cells (Figure 10B). 
In conclusion, the results suggest that AIRE can affect long-range restruc-
turing of chromatin and influence the partitioning of the CEACAM cluster into 
chromatin loops.  
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DISCUSSION 
Since its first identification and initial characterisation, the AIRE protein has 
been associated with many putative functions that contribute to the maintenance 
of immunological tolerance towards self. AIRE has been linked with the de-
termination of the thymic stromal organisation, thymocyte toleration, regulation 
of the immune response and apoptosis of parenchymal cells to facilitate cross-
presentation of self-antigens (Mathis and Benoist, 2007). The strong expression 
of AIRE in mTECs, the protein structure and its localisation to the nucleus 
hinted that AIRE likely binds to chromatin and/or DNA and considering the 
distinct transcriptomic profile of the mTECs, several studies followed up on the 
possible role of AIRE in controlling the gene expression program of these cells 
(Anderson et al., 2002; Derbinski et al., 2001). Indeed, the results causally 
linked the presence of AIRE to the availability of many, albeit not all, self-
antigens in the thymus, which were necessary to avoid autoreactivity by 
preventing self-recognizing thymocytes from leaving the thymus (Kyewski and 
Klein, 2006). Despite of the huge effort by many research groups to reveal the 
molecular mechanisms that make AIRE the ultimate transcription regulator, the 
promiscuous gene expression and the role of AIRE in establishing it remain to 
be elucidated. 
The molecular characteristics that define the functions of a protein often 
include post-translational modifications. The findings of Pitkänen et al. (2000 & 
2005) showing that the transcription coactivator and acetyltransferase CBP 
physically interacts with AIRE and that these two proteins cooperate in the 
regulation of AIRE target genes raised the question about the role of protein 
acetylation by CBP in shaping AIRE activity. In Study I, the immunopre-
cipitation and mass-spectrometric analyses found that 12 out 24 lysines were 
acetylated by CBP and p300. Acetylation occurred at protein sequences that are 
annotated as the nuclear localisation signals and at the putative DNA-binding 
SAND domain. These findings suggested that the acetylation of the AIRE NLS 
could influence the shuttling of AIRE between the cytoplasm and the nucleus, 
while the acetylation of the SAND domain hinted to a possible effect on 
protein-DNA or protein-protein interactions. 
Although the consequences of the acetylation at the NLS were not analysed 
in this study, a later report by Incani et al. (2014) concluded, based on the 
experiments with AIRE acetylation site mutants, that disruption of the 
acetylation at the NLS prevents the correct localisation of the AIRE protein. 
Indeed, acetylation of the NLS is a likely mechanism to regulate protein abun-
dance in subcellular compartments given that this phenomenon has been de-
scribed for many other nuclear proteins (Inuzuka et al., 2012; Matsuzaki et al., 
2005; Ventura et al., 2010). Three acetylation sites were detected at lysines 159, 
164 and 165, which have been suggested to be part of a second NLS, based on 
sequence comparison with other nuclear proteins (Saltis et al., 2008) . 
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However, the function of this sequence has not been tested by mutation 
analysis, and its role as a second NLS remains speculative.  
Study I focused on the acetylation sites in the AIRE SAND domain, which 
has been proposed to mediate interactions with DNA in other proteins, such as 
speckled protein 100 kDa (SP100), the nuclear DEAF1-related protein (NUDR), 
the deformed epidermal autoregulatory factor 1 (DEAF1) and the glucocorticoid 
modulatory element binding protein (GMEB) (Bottomley et al., 2001; Christen-
sen et al., 1999; Gross and McGinnis, 1996). The DNA-binding property of 
AIRE has been mapped to the SAND and PHD domains by electromobility shift 
assays (Kumar et al., 2001; Purohit et al., 2005), but this has not been replicated 
under more physiological conditions in any other study. Moreover, the AIRE 
SAND domain lacks the DNA-binding motif K[DN]WK, which is present in 
other SAND domain-containing proteins (Bottomley et al., 2001). Additionally, 
Ramsey et al. (2002) reported that mutations in the SAND domain affect the 
subcellular localisation of AIRE, which together with the aforementioned 
findings suggest that the AIRE SAND might serve other functions besides inter-
acting with DNA. Therefore, in Study I, acetylation was analysed in the context 
of protein localisation in AIRE nuclear bodies, protein stability and transcrip-
tional activity.  
The protein localisation analysis by immunofluorescence showed that acetyl-
ation of AIRE can influence the size and number of AIRE nuclear bodies. 
Namely, mutations in the AIRE SAND at amino acid positions K243, K245 and 
K253 that mimic the effect of acetylation rendered AIRE to localise into larger, 
but fewer nuclear bodies than wild-type AIRE. Similarly, AIRE formed fewer 
large nuclear bodies after the overexpression of the wild-type p300. In contrast, 
mutations that mimicked unacetylated lysines in the SAND domain or the 
overexpression of the acetyltransferase-deficient p300 did not change the size 
and number of AIRE nuclear bodies compared to the wild-type AIRE. It is 
important to note that the AIRE protein with mutations mimicking acetylation 
did not form aggregates, which were observed by Ramsey et al. (2002) in cells 
expressing the AIRE SAND mutants K221A, K222A, K222E and K253E. This 
suggests that the mutations used in Study I do not disrupt the correct folding of 
AIRE. However, the presence of fewer large AIRE nuclear bodies due to 
acetylation-mimicking mutations or p300 overexpression could be the result of 
stronger hydrophobic interactions between proteins in the nuclear bodies, which 
reduce the mobility and availability of AIRE, because the positive charge of the 
lysine residue is blocked or removed. The AIRE nuclear bodies are bound to the 
nuclear matrix and regarded as transcriptionally inactive structures (Akiyoshi et 
al., 2004; Pitkänen et al., 2005; Tao et al., 2006). Notably, the nuclear matrix 
has been shown to be strongly associated with silenced genomic loci (Croft et 
al., 1999; Scheuermann et al., 2004; Tanabe et al., 2002) . Therefore, the AIRE 
nuclear bodies are positioned close to the regions where AIRE has the greatest 
gene activating effect. Hypothetically, the acetylation of AIRE could be required 
to tighten the contacts with the nuclear matrix, which thereby controls the 
availability of AIRE and its activity. 
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In addition to inflicting changes in protein localisation, the overexpression of 
p300 caused the stabilisation of AIRE protein, which was not observed after the 
overexpression of the acetyltransferase-deficient p300. Protein stability depends 
on another post-translational modification called polyubiquitylation, and it has 
been well established that protein acetylation competes with polyubiquitylation 
for the same lysine residues (Glozak et al., 2005). Indeed, a report by Akiyoshi 
et al. (2004) demonstrated that the AIRE protein is polyubiquitylated and that 
the AIRE nuclear bodies enlarge after the inhibition of the proteasome complex 
due to the retention of the polyubiquitylated AIRE. Furthermore, a recent study 
demonstrates that the ubiquitin ligase FBXO3 is responsible for the ubiquity-
lation of AIRE (Shao et al., 2016). These findings are in line with the protein 
stability assay results in Study I, which suggest that acetylation by p300 can block 
possible polyubiquitylation sites in AIRE and thereby prolong its half-life. 
However, further investigations are required to determine, what is the exact 
interplay between acetylation and polyubiquitylation and how it affects the 
availability of AIRE. 
Interestingly, the acetylation-mimicking mutations in the SAND domain 
significantly reduced the transcriptional activity of AIRE, which was analysed 
by measuring the expression of endogenous AIRE target genes or luciferase 
reporter activity. In contrast, AIRE containing mutations that mimicked unacety-
lated lysines retained the full activity of AIRE. By combining these results with 
the protein localisation data, it could be inferred that the active form of AIRE 
must be unmodified in the SAND domain and dispersed throughout the nucleus. 
These findings are in line with a recent study reporting that an active de-
acetylation by the deacetylase Sirt1 recovers the pool of transcriptionally active 
AIRE in wild-type mTECs (Chuprin et al., 2015). However, Yoshida et al. 
(2015) have determined that the transactivating potential of AIRE does depend 
on the acetylated lysines in the CARD domain, which are a prerequisite for the 
binding to the bromodomain-containing BRD4 protein that recruits P-TEFb, 
which eventually activates the poised RNAP II at silenced loci. Thus, gene 
activation by AIRE seems to require both acetyltransferase and deacetylase 
activities, albeit targeting different parts of the AIRE protein. How the acety-
lation and deacetylation events are temporarily and spatially controlled, remains 
to be explored. 
Additionally, microarray analyses showed that the acetylation-mimicking 
mutations did not repress all AIRE-dependent gene expression, but rather altered 
the selection of target genes. Furthermore, a sizeable fraction of differentially 
expressed genes were shared between cells expressing AIRE.K243/253Q and 
wild-type AIRE compared to the control cell line, which lacked AIRE expression. 
These results suggest that protein acetylation could be a mechanism that helps 
to shape the AIRE target gene repertoire. Importantly, single cell PCR and 
RNA-seq experiments have determined that individual AIRE-positive mTECs 
have apparently distinct and stochastic transcriptional programs (Brennecke et 
al., 2015; Meredith et al., 2015; Sansom et al., 2014). One possible explanation 
for the observed variability of the gene expression could be the level of 
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acetylated AIRE in the individual cells, but the post-translational modifications 
of AIRE in primary thymic stromal cells have not been analysed and further 
testing would be required to confirm or dispute the role of AIRE acetylation in 
TRA gene activation in vivo. In summary, the interaction of AIRE with the 
ubiquitously expressed transcription coactivators and acetyltransferases CBP/ 
p300 has a broad effect on the function of AIRE. 
In Study II, one of the main aims was to structurally and functionally 
characterise the AIRE PHD2 domain by comparing the intact domain to the 
APS1 mutation C446G containing PHD2 domain. The results showed that the 
structure of PHD2 resembles that of a typical PHD domain and the C446G 
mutation completely destroys its fold leading to protein aggregation in the 
cytosol and loss of TRA expression. Interestingly, in vitro pull-down experi-
ments showed that AIRE C446G mutant could still bind histone H3, which is in 
agreement with reports showing that the two AIRE PHD domains function 
independently of each other (Koh et al., 2008; Org et al., 2008). The structural 
analysis in Study II confutes the computational predictions, which suggested 
that the PHD2 domain belongs to the really interesting new gene (RING)-type 
zinc finger domains (Saltis et al., 2008). As a RING-type zinc finger, AIRE 
PHD2 should have possessed ubiquitin ligase activity, but this has never been 
observed. However, AIRE has been shown to function as a E3 ligase, but this 
activity has been mapped to the PHD1 domain instead (Uchida et al., 2004). 
Yet, several independent reports have concluded that the PHD2 domain is 
required for transcriptional control of AIRE target genes (Meloni et al., 2008; 
Uchida et al., 2004; Yang et al., 2013). In the reporter activation experiments 
conducted by Uchida et al. (2004) and Meloni et al. (2008), the analysed PHD2 
mutations disrupted the zinc ion-coordinating cysteines similarly to the C446G 
mutation in Study II. Although the two studies did not analyse protein 
localisation, the observed low or absent transactivation in these studies could be 
attributed to the protein aggregation in the cytoplasm, as seen in Study II. 
Nevertheless, the PHD2 has a more direct influence on AIRE-dependent expres-
sion, which was demonstrated by Yang et al. (2013) using a PHD2 deletion 
knock-out mouse model. Specifically, AIRE without its PHD2 was still able to 
localise into the nucleus, but it could not bind many chromatin- and transcription-
related proteins that would facilitate AIRE-dependent transcription. In conc-
lusion, growing evidence supports the role of the AIRE PHD2 domain in gene 
activation. Future studies addressing the AIRE-regulated transcription, would 
need take advantage of the structural data on AIRE protein domains to design 
mutation analysis experiments that can unravel the molecular events leading to 
TRA expression. 
A substantial part of Study III addressed the question of what happens to the 
chromatin landscape near AIRE target gene loci once AIRE starts to express in 
the cells. First, ChIP experiments demonstrated that the promoter regions of 
AIRE-dependent genes are enriched for the histone variant γH2AX, which acts 
as a marker of double-stranded DNA breaks, and HMGB1, which replaces the 
linker histone H1 at loci that become transcriptionally active (Cato et al., 2008; 
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Lowndes and Toh, 2005). Collectively, these results show that the AIRE-regu-
lated transcription correlates with a more permissive chromatin structure at 
target gene loci. These data complement earlier findings that show an increase 
in histone acetylation and histone H3 lysine 4 methylation levels, both of which 
are associated with transcriptionally active chromatin (Org et al., 2009).  
In addition, the ChIP enrichment of γH2AX and HMGB1 and the loss of 
histone H1 were amplified by the treatment with the TOP2-specific inhibitor 
etoposide suggesting that the altered chromatin structure at AIRE target gene 
loci heavily depends on the activity of TOP2. TOP2A is a major interaction 
partner of AIRE, and the inhibition of its religation activity by etoposide has 
been shown to activate several AIRE-dependent genes in HEK293 cells, which 
has highlighted the role of DNA breaks in AIRE-regulated transcription 
(Abramson et al., 2010). Notably, Abramson et al. also reported that the AIRE-
positive MHCIIhi-expressing mTECs in wild-type mice have more DNA breaks 
compared to AIRE knock-out littermates. In summary, the analysis of etoposide 
treated AIRE-expressing cells reveals a strong link between DNA breaks, 
AIRE-dependent transcription and chromatin structure. 
In Study III, the FAIRE-seq approach was used to test, whether besides the 
altered enrichment of chromatin proteins, it would be possible to detect changes 
in open chromatin regions, which would identify transcription factor binding 
sites that are utilised in AIRE-expressing AIRE-Tet cells. The analysis revealed 
that many promoter regions become less open in AIRE-expressing cells, but 
interestingly, relatively few changes were detected within or near AIRE-regu-
lated genes. Although FAIRE-seq does not identify the specific transcription 
factors, it could hint to some molecular events that are put into motion by AIRE. 
First, based on published ChIP-seq data, AIRE has been shown to bind to 
almost all promoters irrespective of the transcriptional status of the genes (Giraud 
et al., 2012), and therefore, it would be likely that the open chromatin regions 
are occupied by AIRE itself. This possibility, however, was not addressed in 
Study III. Second, open chromatin could be taken over by histones or other 
chromatin-related proteins.  
Indeed, a large fraction of AIRE-related structural changes in chromatin 
occurred at CTCF binding sites that are considered to define genomic boun-
daries between active and silenced chromosomal regions (Nora et al., 2012; 
Zuin et al., 2014; Tark-Dame et al., 2014). This observation raised the notion 
that AIRE-dependent transcriptional control requires the rearrangement of 
chromatin interactions between distant regions. It would be feasible to speculate 
that the genomic boundaries have to be redefined in AIRE-expressing cells to 
allow the transcriptional machinery to enter and interact with the silenced AIRE 
target gene regions. This hypothesis was analysed with the chromosome con-
formation capture assay, which showed that the CTCF-mediated chromatin 
interaction frequencies change at least in the CEACAM gene cluster in AIRE-
expressing cells compared to AIRE-negative AIRE-Tet cells. These structural 
changes at CTCF sites could affect promoter-enhancer interactions and 
modulate the transcriptional permissiveness of AIRE target genes. However, 
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further exploration of the epigenetic profiles and genome-wide chromatin inter-
action maps are required to comprehensively determine the interplay between 
the underlying chromatin structure and the transcriptional program of AIRE-
expressing cells.  
In conclusion, the current thesis highlights the role of post-translational 
acetylation in the stability and transcriptional activity of AIRE. Additionally, 
structural analysis in combination with protein localisation studies showed that 
the C446G mutation in the AIRE PHD2 domain causes protein aggregation, 
which prevents AIRE from entering the cell nucleus, thus effectively blocking 
AIRE-dependent transcription. Interestingly, the intact AIRE protein not only 
controls the activation of thousands of silenced genes, but also affects 
chromatin structure throughout the genome. However, more in-depth studies are 
needed to elucidate the cause-and-effect relationships that exist between the 
chromatin conformation and AIRE-regulated gene activation. Presumably, it 
would lay a solid basis to fully understand the still enigmatic molecular mecha-
nisms of promiscuous gene expression and immune tolerance.  
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CONCLUSIONS 
1. The AIRE protein is extensively acetylated by p300 in HEK293 cells. The 
acetylated lysines are part of critical sequences in the nuclear localisation 
signal and the SAND domain. The acetylation affects the stability of the 
AIRE protein and the size and number of AIRE nuclear bodies. Mutation 
analyses highlight the role of the acetylated lysines in the transcriptional 
control of AIRE-dependent genes. 
2. The previously identified APS1-associated mutation C446G in AIRE PHD2 
domain destroys the structure of the PHD finger and hinders the correct 
subcellular localisation of AIRE into the nucleus. Although the C446G 
mutation permits the binding of AIRE to histone H3, which is a critical 
interaction for the transactivation of AIRE-dependent genes, this mutation 
abolishes the capacity of AIRE to activate its target genes. This suggests that 
the correct folding of the PHD2 zinc finger plays a critical role in 
establishing AIRE-regulated gene expression. 
3. The activation of AIRE target genes coincides with changes in chromatin 
accessibility at promoter regions of AIRE-independent genes: apparently, 
chromatin accessibility decreases whereas a large fraction of those sites 
overlaps with CTCF binding sites. The interaction frequency between CTCF 
binding sites at the CEACAM gene cluster is altered in AIRE-expressing 
cells. Jointly, this means that AIRE affects large-scale rearrangements of the 
chromatin structure at AIRE target gene loci.  
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SUMMARY IN ESTONIAN 
AIRE mõju geeniekspressioonile – transkriptsiooni regulatsiooni 
mehhanismi uuringud koekultuuri rakkudes 
Immuunsüsteemi põhiline ülesanne on ära tunda ja võidelda patogeenidega, mis 
üritavad tungida organismi ning seda kahjustada. Samaväärselt oluline on orga-
nismi seisukohast immuunsüsteemi võime ära tunda omaenda kehale omaseid 
või väljastpoolt tulevaid kahjutuid molekule ning hoiduda nende vastu suunatud 
immuunreaktsiooni tekitamisest. Seda nähtust nimetatakse immuuntolerantsu-
seks. Üks peamisi immuuntolerantsuse kujunemise organeid on harknääre ehk 
tüümus, mis vastutab kehaomaseid valke tundvate T-lümfotsüütide elimineeri-
mise eest. Nimelt reageerivad arenevad T-lümfotsüüdid T-raku retseptori kaudu 
tüümuse medullaarsete epiteelirakkude pinnal olevate koesobivuskompleksi-
dega. Antud kompleksid kannavad enda küljes kehavalkudest pärit peptiide, 
mille suhtes spetsiifilise T-raku retseptoriga T-lümfotsüüt suunatakse apoptoosi. 
T-lümfotsüüdid, mis reageerivad nõrgalt või ei reageeri üldse kehaomaste pep-
tiididega, jäävad ellu ning pääsevad küpsete naiivsete T-rakkudena tüümusest 
välja vere- ja lümfiringesse. Tüümuse medullaarsed epiteelirakud on võimelised 
avaldama hämmastavalt suurt osa kõigist organismi valke kodeerivatest geeni-
dest, sealjuures ülimalt koespetsiifilisi geene. Paljuski sõltub see n-ö. avatud 
geeniekspressioon ühe transkriptsiooni reguleeriva valgu olemasolust, milleks 
on AIRE (autoimmune regulator). Mutatsioonid AIRE geenis võivad põhjustada 
1. tüüpi autoimmuunset polüendokrinopaatia sündroomi (APS1). Kuna AIRE 
puudumise tõttu ei avaldu koespetsiifilised geenid, siis jäävad autoreaktiivset  
T-raku retseptorit kandvad T-lümfotsüüdid ellu, pääsevad vere- ja lümfiringesse 
ning ründavad keha enda kudesid. Lisaks tekivad APS1 korral kudede vastu 
suunatud autoantikehad. APS1 raskusaste ja sümptomite spekter on väga 
varieeruvad, kuid kõige sagedamini esinevad patsientidel kõrvalkilpnäärme ala-
talitlus ja neerupealiste puudulikkus. Seennakkuste vastu võitlemiseks vajalike 
tsütokiinide vastaste autoantikehade tõttu tekib peaaegu kõigil patsientidel 
kandidoos. 
Alates AIRE geeni ja valgu kirjeldamisest 1997. aastal on palju tähelepanu 
pööratud protsessidele, mis võimaldavad AIRE valgul käivitada tuhandete 
geenide avaldumise, mis AIRE puudumisel on üldjuhul vaigistatud. Intensiivse 
uurimistöö tulemusel on selgunud, et AIRE seondub paljude geeniekspressiooni 
mõjutavate valkudega ja seeläbi kasutab ära teiste valkude omadusi, et regu-
leerida geenide avaldumist eelkõige transkriptsiooniliselt inaktiivsetes genoomi 
piirkondades. Kahe iseseisva proteoomiuuringu tulemuste põhjal on kindlaks 
tehtud, et AIRE interakteerub väga laia valkude repertuaariga, mida võib nende 
funktsiooni alusel jagada 4 suuremasse rühma. Nendeks on transkriptsioonis, 
kromatiini struktuuris ja remodelleerimises, RNA splaissingus ja rakutuuma 
transpordis osalevad valgud. Järk-järgult on selgunud, millistes etappides on 
need kirjeldatud valgud AIRE poolt reguleeritava transkriptsiooni jaoks vajalikud. 
AIRE interaktsioonipartneritest üks olulisemaid ning rakutuuma valkudest 
sagedasemaid on histooni H3 selline variant, mida leidub üldjuhul just vaigis-
tatud genoomsetes piirkondes. AIRE seondub transkriptsiooni elongatsiooni-
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faktoritega, mis aitavad RNA polümeraasi aktiveerida, ning rakutuumas paikne-
vate ensüümidega, mis parandavad polümeraasi liikumise käigus tekkivaid 
DNA katkeid. Lisaks on AIRE omadust aktiveerida just vaigistatud geene püü-
tud seletada sellega, et AIRE interakteerub transkriptsiooni represseeriva valgu-
kompleksiga, mis osaleb heterokromatiinile omase histoonimodifikatsiooni-
mustri loomisel ning seondub metüülitud CpG dinukleotiididega vaigistatud 
genoomsetes piirkondades. Siia tuleb veel märkida, et on kirjeldatud ka AIRE 
seondumist kromatiniseerumata DNA molekuliga, leides, et sel juhul toimub 
geeni aktivatsioon sõltumatult regulatoorsete järjestuste, nagu promootori või 
mittetransleeritavate 5’ ja 3’ järjestuste olemasolust. Sellise interaktsiooni roll 
koespetsiifiliste geenide transkriptsiooni käivitamisel tüümuse medullaarsetes 
epiteelirakkudes on veel ebaselge. 
Käesoleva uurimistöö esimene osa lähtus varasematest tulemustest, mis näi-
tasid, et AIRE seondub CBP-ga ja seeläbi võimendub AIRE sihtmärkgeenide 
ekspressioon. Kuna CBP atsetüültransferaasse aktiivsuse rolli selles protsessis 
ei oldud kirjeldatud, keskenduti esmalt küsimusele, kas AIRE ja CBP interakt-
siooni üheks tagajärjeks on AIRE valgu atsetüülimine. Immuunosadestamise ning 
mass-spektromeetrilise analüüsi põhjal leiti, et vähemalt pooled AIRE valgu 
järjestuses olevad lüsiinijäägid on CBP ja tema paraloogi, p300, poolt atsetüüli-
tud. Antud katsetest selgus, et atsetüülimine toimub CARD ja SAND domeeni 
vahelises osas, kuhu jääb tuumalokalisatsioonisignaali järjestus, ning SAND 
domeeni sees. Edasine tähelepanu koondus atsetüülimisele, mis toimub SAND 
domeenis, mida varasemates töödes on kirjeldatud kui DNA-ga seonduvat 
järjestust. Atsetüülimine võib mõjutada valgu lokalisatsiooni, tema stabiilsust ja 
võimet interakteeruda DNA või teiste valkudega. Leiti, et p300 üleekspressiooni 
järel muutuvad AIRE tuumakehad suuremaks, kuid nende arv väheneb. Samuti 
täheldati, et AIRE valk laguneb palju aeglasemalt, vihjates sellele, et atsetüüli-
tud lüsiinijäägid võivad olla substraadiks polüubikvitineerimisreaktsioonidele, 
mis suunavad valgu lagundamisele proteasoomide poolt. Valitud AIRE siht-
märkgeenide avaldumist p300 üleekspressioon ei mõjutanud, kuid teatud AIRE 
SAND domeenis olevate atsetüülitavate lüsiinide asendamine glutamiinidega, 
mis positiivse laengu puudumise ning külgahela struktuuri tõttu mimikeerivad 
atsetüülitud lüsiine, vähendas tunduvalt AIRE poolt reguleeritavate geenide 
avaldumist. Samas AIRE säilitas täielikult oma transaktivatsioonivõime, kui 
lüsiinid olid asendatud arginiinidega, mis sarnaselt atsetüülimata lüsiinidele 
kannavad positiivset laengut. Ülegenoomi ekspressioonianalüüsiga tuvastati, et 
atsetüülimist mimikeerivate mutatsioonidega AIRE valk ei kaota täielikult oma 
transaktivatsioonivõimet, vaid muutub sihtmärkgeenide valik, mis siiski kattub 
osaliselt ka metsiktüüpi AIRE valgu poolt reguleeritavate geenide nimekirjaga. 
Töö teises osas analüüsiti APS1 patsientidel leitud AIRE PHD2 domeenis 
esineva missense mutatsiooni C446G mõju domeeni struktuurile ja AIRE funkt-
sioonile. Selgus, et antud mutatsioon lõhub täielikult PHD2 domeeni kooshoid-
miseks vajaminevad sidemed Zn2+ ioonide ning aminohapete vahel. Selle tule-
museks on AIRE valk, mis agregeerub tsütosoolis ning ei pääse seetõttu rak-
tuuma, et käivitada seal oma sihtmärkgeenide avaldumine. Huvitaval kombel 
selgus, et GST liitvalguna ekspresseeritud C446G AIRE mutatsiooniga valk 
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seondus in vitro seondumiskatsetes endiselt histoon H3-ga, mis on kriitiliselt 
oluline AIRE sihtmärkgeenide aktiveerimiseks. Sellest võib järeldada, et õige 
lokalisatsiooni korral suudaks antud mutatsiooniga AIRE valk tagada sihtmärk-
geenide ekspressiooni. Seda oletust toetavad katsed, mis on tehtud ilma PHD2 
domeenita AIRE valguga, mis ei agregeeru ning on endiselt transkriptsiooni-
liselt aktiivne. 
Töö kolmanda osana analüüsiti AIRE ja TOP2A valkude koostoimet AIRE 
sihtmärkgeenide transkriptsioonile. Varasemalt avaldatud töös leiti, et TOP2A 
DNA ahelaid ligeeriva ensümaatilise aktiivsuse pärssimine etoposiidiga käivitab 
sarnase transkriptioonilise programmi, nagu see on AIRE üleekspressiooni 
korral ja AIRE ning etoposiidi koostoimel ei ole teineteist täiendavat efekti. 
Käesolevas uuringus leiti, et AIRE valku ekspresseerivates rakkudes võib 
madala etoposiidi kontsentratsiooni juures toimuda väga võimas AIRE siht-
märkgeenide avaldumise tõus. Etoposiidi töötlus stabiliseerib DNA katked 
genoomis ja DNA katketega piirkondi iseloomustab histoon γH2AX rikastuse 
tõus. Antud juhul suurenes γH2AX rikastus AIRE sihtmärkgeenide lähedal. 
Sihtmärkgeenide promootoralades esines ka rohkem HMGB1 valku, mis ise-
loomustab transkriptsiooniliselt aktiivset ning avatud kromatiini struktuuri, ning 
vähenes linkerhistooni H1 hulk, mida seostatakse vaigistatud kromatiini 
olekuga. Nende tulemuste põhjal tehti ülegenoomi sekveneerimise katse, et 
tuvastada genoomsed piirkonnad, mille avatus muutub AIRE olemasolust tingi-
tult. Leiti, et AIRE juureolekul ning eriti juhul, kui AIRE-t ekspresseerivaid rakke 
oli töödeldud etoposiidiga, kaotasid paljud piirkonnad oma avatuse. Eelkõige 
toimusid muudatused geenide promootoralades, kuid huvitaval kombel oli 
nende hulgas väga vähe AIRE poolt reguleeritud geenide promootoralasid. 
Üldiselt toimusid muutused AIRE sihtmärkgeenidest kaugel, kuid need piir-
konnad kattusid olulisel määral CTCF valgu seondumispiirkondadega. CTCF 
valku peetakse oluliseks kromatiini struktuuri loovaks valguks, luues valk-DNA 
ja valk-valk interaktsioonide kaudu kromatiini lingusid. Järgnevalt testiti, kas 
mitmeid AIRE sihtmärkgeene sisaldava CEACAM geeniklastri sees ja servades 
olevate CTCF seondumiskohtade vahel on võimalik detekteerida interaktsioo-
nide sageduse muutuseid, kasutades selleks 3C meetodit. Tulemustest selgus, et 
AIRE juuresolekul tõepoolest tõuseb teatud interaktsioonide sagedus, samal ajal 
kui teiste interaktsioonide sagedus langeb. 
Kokkuvõtvalt võib öelda, et post-translatsiooniline atsetüülimine mõjutab 
olulisel määral AIRE valgu stabiilsust ning transkriptsioonilist aktiivust. Lisaks 
tehti kindlaks, et APS1 patsientidel leiduv C446G mutatsioon AIRE PHD2 
domeenis põhjustab AIRE valgu agregeerumist, mis takistab AIRE-l liikuda 
tsütoplasmast rakutuuma, et seal käivitada oma sihtmärkgeenide ekspressioon. 
Huvitaval kombel on intaktne AIRE võimeline mitte ainult aktiveerima tuhan-
dete vaigistatud geenide avaldumist, vaid ka mõjutama kogu genoomi ulatuses 
kromatiini struktuuri. Siiski on vajalikud täpsemad uuringud, et selgitada, millised 
põhjus-tagajärg seosed valitsevad kromatiini struktuuri ja AIRE poolt reguleeri-
tava transkriptsiooni vahel, mis eeldatavasti looks hea aluse senini enigmaati-
lisena püsinud avatud geeniekspressiooni ja seeläbi immuuntolerantsuse mole-
kulaarsete mehhanismide täielikuks mõistmiseks. 
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